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Stellingen behorende bij het proefschrift 
Adenosine and its receptors 
Translational studies in asthma and COPD 
1 Met het gebruik van leukemische cellen kun je tot een antwoord op je 
vraagstelling komen, maar toetsing in primaire cellen blijft noodzakelijk. 
(dit proefschrift) 
2 Het gebruik van een specifieke antagonist voor A28R is van belang om 
de betrokkenheid van deze receptor bij degranulatie van mestcellen te 
bevestigen. (ditproefschrift) 
3 Specifieke antagonisten voor A28R en specifieke agonisten voor Ay_R kunnen 
bijdragen in de behandeling van astma. (dit proefschrift) 
4 Adenosine en zijn receptoren spelen een belangrijke rol bij de pathofysiologie 
van astma en COPD. (dit proefschrift) 
5 Het degranulerend effect van sigaretten rook (extract) op de mestcel 
suggereert dat de mestcel een centrale rol heeft bij de AMP-geinduceerde 
hyperreactiviteit in astma en COPD. (dit proefschrift) 
6 Dat het bij de eerste poging lukt om primaire mestcellen te kweken, duidt 
meer op beginnersgeluk dan op een waterdicht protocol. 
7 Een mestcel kun je zien als een vulkaan, hij kan slapend (aanwezig) zijn, 
maar ook heel veel schade aanrichten. 
8 De organisatie van patientenstudies meet aan artsen overgelaten worden 
en het labwerk aan biologen. 
9 Het rookverbod in de horeca maakt het voor COPD-patienten gemakkelijker 
om te stoppen met roken. 
10 Muziek en wetenschap zijn beide creatieve bezigheden waarbij een goede 
compositie meer indruk maakt dan enkele losse noten. 
Mieke Versluis 
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This thesis deals with the role of adenosine receptors in asthma and COPD. The 
introduction first highlights the diseases asthma and COPD and explains the 
possible role for adenosine and adenosine receptors. Thereafter, the aims of the 
different thesis chapters will be presented. 
Asthma 
Asthma is defined by the Global Initiative for Asthma (GINA) (1) as na chronic 
inflammatory disorder of the airways in which many cells and cellular elements play 
a role. The chronic inflammation is associated with airway hyper responsiveness 
that leads to recurrent episodes of wheezing, breathlessness, chest tightness, 
and coughing, particularly at night or in the early morning. These episodes are 
usually associated with widespread, but variable, airflow obstruction within the 
lung that is often reversible either spontaneously or with treatment'� There 
has been a sharp increase in the global prevalence, morbidity, mortality, and 
economic burden associated with asthma over the last 40 years, particularly in 
children. Approximately 300 million people worldwide currently have asthma, and 
its prevalence increases by 50% every decade (2). A prevalence of 15-20% in 
adults has been described in the Netherlands (3). An active inflammatory process 
is present in the airways of asthmatic patients, even when they appear to be 
asymptomatic (4). This inflammation is characterized by degranulation of mast 
cells and mucosa! infiltration of eosinophils and lymphocytes (5). Also deposition of 
collagen beneath the basal membrane, hyperplasia and hypertrophy of bronchial 
smooth muscle cells and hyperplasia of goblet cells occurs in the airways of 
asthmatic subjects (6). 
Narrowing of the airways can occur by smooth muscle contraction, oedema and 
swelling of the airway wall, increased mucus in the airways and remodelling of 
the airway wall and surrounding lung tissue (7). Many cells and cellular elements 
play a role in the development and severity of asthma (1;8). This inflammation 
contributes also to the airway obstruction that is caused by inhalation of allergens. 
Allergen inhalation typically induces both an early response, with airway obstruction 
within 10 minutes, and a late response that usually is associated with airway 
obstruction after 8-24 hours. The late response is accompanied by an increase in 
airway hyperresponsiveness (AHR). AHR is the phenomenon that asthma patients 
respond with airway obstruction when inhaling non-allergic triggers present in the 
environment, like cigarette smoke, cold air, or fog, to which healthy individuals 
do not respond. As such, AHR is considered as a hallmark of asthma. Since AHR 
increases after inhalation of an allergen, a trigger known to attract inflammatory 
cells to the airway walls, it is clear that airway inflammation underlies both 
the allergen induced airway obstruction and the non-allergic induced airway 
obstruction. AHR is usually measured in the laboratory by inhalation of histamine 
or methacholine that directly act on smooth muscle cells, thereby inducing 
smooth muscle constriction. It can also be measured by inhalation of adenosine-
5'-monophosphate (AMP) that indirectly leads to smooth muscle contraction, e.g. 
via histamine release from mast cells that contain adenosine receptors on their 
surface. AMP responsiveness is a risk factor for asthma development (9) and also 
reflects the inflammatory process in the airways of asthma patients better 
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Figure 1. Pathogenesis of asthma 
After exposure to an allergen (e.g. house dust 
mite, pollen or dander), epithelial cells produce 
cytokines that recruit leukocytes from peripheral 
blood and the surrounding tissue, also smooth 
muscle hypertrophy can occur. 
than when measured with methacholine (10). The inflammatory cells present in 
asthma characteristically include eosinophils, T lymphocytes, mast cells, and, in 
case of more severe asthma, neutrophilic granulocytes. 
COPD 
Chronic Obstructive Pulmonary Disease (COPD) is defined by the Global Initiative 
for Chronic Obstructive Lung Diseases (GOLD) as "a preventable and treatable 
disease with some significant extra pulmonary effects that may contribute to 
the severity in individual patients. Its pulmonary component is characterized 
by airflow limitation that is not fully reversible. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory response of the lung 
to noxious particles or gases" (11). COPD is mainly caused by tobacco smoking 
and environmental pollutants, and expected to be the third most important 
cause of death and the fifth leading cause of disability-adjusted life years lost by 
2020 (11). It has a large impact on the economic and social burden throughout 
the world. COPD is characterised by chronic airway obstruction that progresses 
slowly over the years, which is often accompanied by respiratory symptoms, like 
cough, phlegm, and dyspnea. The severity of COPD is marked by a lower lung 
function (FEV1 and FEV/Vital Capacity (VC) ratio) and an accelerated decline in 
FEV1 • AHR is common in these patients and its severity contributes to the rate of 
lung function decline. The inflammatory cells present in the airway wall in COPD 
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Figure 2. Pathogenesis of COPD 
Introduction 
Under influence of exposure to cigarette smoke, 
epithelial cells produce cytokines to recruit 
leukocytes (e.g. monocytes, lymphocytes, 
and neutrophils) from peripheral blood and 
surrounding tissue, and leads to increased 
protease presence and oxidative stress 
Pathological changes in the airways that contribute to airway obstruction in COPD 
are an increase in 1) the number and size of glands, 2) inflammation, 3) fibrosis, 
and 4) destruction of alveolar attachments. 
There is no cure available as yet for patients with COPD. The current best 
treatment for COPD is smoking cessation, since it decreases chronic symptoms and 
slows down the accelerated decline in FEV1 (12-14). In order to develop new and 
effective therapies, one needs to understand the pathophysiological mechanisms 
underlying COPD. Two important components of COPD that contribute to its 
clinical disability are the presence of AHR and (extra) pulmonary inflammation. 
AHR occurs in about 70% of all patients with COPD. Interestingly, we and others 
have found that smokers with COPD are responding to inhalation with AMP (15-
17), reflecting the increased sensitivity of the airways to adenosine. Therefore, 
adenosine receptors may be of importance in COPD and associated with disease 
severity and/or progression. More knowledge on adenosine-related mechanisms 
may open new treatment avenues in the future for this severe disease. 
Adenosine and adenosine receptors 
A wide variety of cells, but also a variety of mediators play a role in the ongoing airway 
inflammation present in asthma, adenosine being one such a mediator. Adenosine 
is a natural occurring purine nucleoside that is released as a breakdown product 
of the energy metabolism and AMP during tissue hypoxia and inflammation. AMP 
becomes dephosphorylated to adenosine by ecto-5'-nucleotidase, present on the 
cell membrane, and can display both pro- and anti-inflammatory activities in cells 
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and tissues. Adenosine has been found in high concentrations in bronchoalveolar 
lavage fluid of patients with exercise- and allergen-induced asthma (18) and the 
discovery that adenosine levels are elevated in the bronchoalveolar lavage fluid of 
asthmatics and increase further after allergen challenge raises the possibility that 
adenosine generated in asthmatic airways itself contributes to the pathogenesis 
of asthma (18;19). 
An explanation for this finding could be that stimulation of inflammatory cells 
and subsequent smooth muscle contraction during the asthmatic inflammatory 
process leads to an increase in oxygen and energy demand, thus leading to an 
increase in the level of adenosine in the airways in asthma. 
Extra cellular adenosine can mediate its effects via four known adenosine 
receptors, adenosine A1, A2A' A28, and A3 receptors, which belong to the family of 
G-protein-coupled receptors. A2AR and A28R subtypes mediate anti-inflammatory 
functions by coupling adenylyl cyclase (AC) stimulating Gs -proteins, which results 
in intracellular cAMP increase and down-regulation of cytokine gene expression 
(20-22), T-cell proliferation (23) and FcERI-mediated mast-cell degranulation 
(24). A1 R and A3R subtypes mediate pro-inflammatory functions by coupling 
AC inhibiting Gi-proteins, which results in an intracellular cAMP decrease and 
initiation of neutrophil chemotaxis (25) and apoptosis and intracellular Ca2+ 
increase in eosinophils (26;27). Figure 3 shows different inflammatory cells for 




Figure 3. Adenosine 
receptor expression by 
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Introduction 
Despite some knowledge on the function of adenosine receptors, their role in 
asthma and COPD has been scarcely investigated. Notwithstanding this, the 
interest in these receptors has been raised in the past decade since it has been 
acknowledged that their pro- and anti-inflammatory capacity may provide targets 
for new drugs. 
Mast cells 
Mast cells are resident in all normal tissues, where they are believed to play an 
important role in tissue homeostasis, wound healing, and host defence (28;29). 
They are located at strategic sites such as the skin, and vascular and mucosa! 
barriers. Mast cells bind IgE on their surface by expressing the high-affinity Fe 
receptor for IgE and release histamine and other mediators after cross-linking 
of surface-bound IgE by allergen (30). AHR upon AMP inhalation is believed to 
occur mainly by degranulation of mast cells, in which A28R has a prominent role 
in the induction of degranulation (31), and A2AR in the inhibition of degranulation 
(24;32;33) (figure 4). 
Since it is hard to obtain primary mast cells from the lung, the human mast cell 
line 1 (HMC-1) has been used as a model to investigate degranulation of mast 
cells upon adenosine receptor activation. This HMC-1 cell line is derived from a 
mast cell leukaemia patient and lacks the presence of functional high affinity IgE 
receptors; expression of the adenosine receptors A2AR, A28R, and A3R on HMC-1 
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Aims and outline of this thesis 
This thesis deals with several studies aiming to elucidate the role of adenosine 
receptors in asthma and COPD. To this aim both in vitro studies in cell systems 
and studies in human subjects with asthma or COPD have been performed. 
Chapter 2 presents an overview on the different adenosine receptors and their 
potential role in inflammatory lung disease, together with the possible role of 
adenosine receptors in treatment of asthma and COPD. 
Chapter 3 presents the effects of incubation of HMC-1 cells with the inflammatory 
cytokines IL-4 and IL-13 in combination with AMP stimulation on adenosine receptor 
expression and mediator secretion by mast cells, to investigate a relationship 
between adenosine responsiveness of mast cells and asthma. 
Chapter 4 presents the comparison of asthmatics and healthy subjects with 
respect to adenosine receptor expression on inflammatory cells in sputum and 
peripheral blood. Furthermore the effect of allergen challenge on inflammatory 
cells, cytokine production, and adenosine receptor expression in asthmatics was 
investigated. 
Chapter 5 presents the effect of cigarette smoke extract on adenosine 
responsiveness and adenosine receptor expression of HMC-1 cells, in order to 
explain AMP responsiveness in smoking COPD patients. 
Chapter 6 presents whether adenosine-related effector mechanisms are 
involved in the persistence and progression of the inflammatory response in 
COPD following 1-year smoking cessation. 
Chapter 7 summarizes and discusses the results obtained in chapters 3-6 and 
will conclude with directions for future research. 
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Abstract 
Adenosine is a naturally occurring purine nucleoside with a ubiquitous presence in 
human tissue playing a key role in many biological processes such as energy gen­
eration and protein metabolism. It has been shown that adenosine induces bron­
choconstriction in asthmatic and COPD patients, but not in normal airways. Four 
different G-protein coupled adenosine receptors have been described, namely 
adenosine A11 A2A, A28, and A3 receptors. The main mechanism of adenosine-in­
duced bronchoconstriction appears to involve the release of inflammatory media­
tors from mast cells via activation of the A28 receptor. However, adenosine can 
also act on A1, A2A and A3 receptors. In recent years there has been an increasing 
interest in the role of adenosine receptors in asthma and COPD, since it is now 
clear that adenosine receptors play an important role in the pathophysiology of 
asthma and COPD. They are involved in the production and release of a variety 
of mediators from inflammatory and structural cells. A therapeutic potential of 
adenosine receptor modulation has even been anticipated. This review will focus 
on the role of adenosine and adenosine receptors in the treatment of asthma and 
COPD. 
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Introduction 
Adenosine is a naturally occurring purine nucleoside with a ubiquitous presence 
in human tissue playing a key role in many biological processes such as 
energy generation and protein metabolism. It has been shown that the stable 
form of adenosine, the nucleotide adenosine-monophosphate (AMP) induces 
bronchoconstriction in asthmatic, but not in normal airways (1). AMP can induce 
bronchoconstriction in COPD as well. Hyperresponsiveness to AMP has a higher 
prevalence and severity in smokers than in non-smokers (or ex-smokers) with 
COPD who have similar levels of hyperresponsiveness to methacholine (2). 
Several in vitro and clinical studies suggest that the main mechanism of adenosine­
induced bronchoconstriction involves the release of inflammatory mediators from 
mast cells. Firstly, adenosine was shown to enhance the release of a variety 
of inflammatory mediators like histamine, prostaglandins, leukotrienes, and 
interleukin-8 (IL-8) in vitro, by human mast cells (3;4). Secondly, it has been found 
that endobronchial instillation of AMP results in an immediate increase in the level 
of both histamine and the (mast cell specific) protease tryptase in bronchoalveolar 
lavage fluid (5-7). It is likely that the release of histamine is mast cell rather than 
basophil derived, since sodium cromoglycate and albuterol have been shown to 
effectively inhibit AMP-induced bronchoconstriction, but have no activity against 
histamine release from basophils (8-10). Thirdly, the potent and selective histamine 
receptor-antagonists terfenadine and astemizole have been shown to potently 
inhibit the bronchoconstrictor response to adenosine both in asthma and COPD, 
suggesting that histamine is the predominant mast cell mediator involved in the 
airway response to this nucleotide (11-13). Enhancement of mast cell mediator 
release, although prominent, may not be the only mechanism of action of AMP. 
Activation of neural pathways may also contribute to the bronchoconstrictor 
response to adenosine, although this subject remains controversial (13;14). The 
discovery that adenosine levels are elevated in bronchoalveolar lavage fluid and in 
exhaled breath of asthmatics and increases further after allergen challenge raises 
the possibility that adenosine itself, once generated in the airways, contributes to 
the pathophysiology of asthma (figure 1) (15) .  There are several lines of evidence 
that adenosine and adenosine receptors may play a role in the pathophysiology of 
COPD as well. Adenosine levels are higher in the bronchoalveolar lavage fluid of 
smokers (without COPD) than in non-smokers (15). Further, it has been shown by 
Varani and colleagues that the level of expression of adenosine receptor subtypes 
differs between patients with COPD and age-matched smokers with a normal 
lung function (16). In this context, it is of interest that IL-4 induces an increase in 
adenosine A1, A28, and A3 receptors in C57BL/6 mice (which are prone to develop 
emphysema when exposed to cigarette smoke), but not in Balb/c mice (which 
do not develop emphysema when exposed to cigarette smoke) (17). This review 
will focus on the role of adenosine and adenosine receptors in the treatment of 
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Figure 1. Schematic diagram of the mechanisms involved in adenosine-induced bronchocon­
striction. Once generated, adenosine activates the adenosine A28 receptor on mast cells. Upon 
activation of the adenosine A28 receptor various inflammatory mediators are released which induce 
bronchoconstriction. (adapted with permission from Hasko and colleagues, Trends Immunology 
2004). ADP = adenosine diphosphate; AMP = adenosine monophosphate; AT P = adenosine 
triphosphate; NT = nucleotidase; NTPD = nucleoside triphosphate diphosphohydralase. 
Adenosine and adenosine receptors 
Endogenous adenosine derives from dephosphorylation of the nucleotide 
adenosine-monophosphate (AMP) to adenosine by the enzyme 5'-nucleotidase, 
which has a ubiquitous presence in the cell membrane. AMP is formed by the 
catabolism of high-energy adenosine phosphates such as adenosine diphosphate 
(ADP) or adenosine triphosphate (ATP) during the process of energy generation. 
When sufficient oxygen and energy is available, AMP is reconverted to high­
energy phosphates. However, in case of high energy demand during excessive 
cell stimulation or hypoxia, AMP can not be reconverted and is transported to 
the exterior of the cell where it is metabolized to adenosine by the enzyme 
5'-nucleotidase. The ability of the adenosine uptake inhibitor dipyridamole to 
enhance adenosine-induced effects led to the suggestion that the action of 
adenosine is likely mediated through stimulation of specific receptors located on 
the cell surface (18). Four different G-protein coupled adenosine receptors have 
been described, namely adenosine A1, A2A' A28, and A3 receptors (19). Adenosine 
A1 and A3 receptors are Gtprotein coupled receptors. Their activation decreases 
adenylyl cyclase activity and cAMP. In contrast, adenosine A2A and A28 receptors 
are Gs -protein coupled receptors and their activation increases adenylyl cyclase 
activity and cAMP (20). Interestingly, adenosine A28 receptors are additionally 
coupled to G -proteins, which results in activation of phospholipase C upon 
binding. Phospholipase C splices phosphatidylinositol-4,5 bisphosphate, thereby 
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inducing diacylglycerol and inositol triphosophate. Diacylglycerol activates protein 
kinase C and inositol triphosphate activates calcium channels, both of which are 
necessary for the fusion of granules of mast cells with the plasma membrane 
(21;22). This may explain that activation of adenosine A28 receptors, but not 
adenosine A2A receptors, induces the release of mast cell mediators. In addition, 
adenosine A1 and A3 receptors can also activate potassium and calcium channels 
and for adenosine A2A and A28 receptors cAMP-independent intracellular pathways 
have been described as well (23). As animal models have become available, it is 
now clear that the adenosine receptor subtypes involved in adenosine-induced 
bronchoconstriction (and inflammatory responses) vary among species. In 
humans, adenosine-induced bronchoconstriction is mediated by A28 receptors, 
in the rabbit by A1 receptors, in the rat by A1, A28 and A3 receptors, in the guinea 
pig by A3 receptors and in the mouse by A28 and A3 receptors (24-26). Although it 
is now clear that adenosine and adenosine receptors contribute to the presence 
and extent of airway inflammation, the exact role of each adenosine receptor 
subtype and their interaction is yet unknown. 
See table 1 for selective adenosine agonists and antagonists currently used in 
preclinical and clinical studies. 


























High expression of adenosine A1 receptors has been found in the brain, spinal 
cord, eye and adrenal gland, intermediate expression in skeletal muscles and 
gastro-enteric tract, whereas low expression has been found in lungs and bronchi 
(23). In addition, adenosine A1 receptors are present on human neutrophils and 
their activation promotes chemotaxis of neutrophils and increased adherence 
of neutrophils to endothelial cells (27;28). It has been suggested by McNamara 
and colleagues that adenosine A1 receptors may have pro-inflammatory effects. 
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They demonstrated that adenosine A1 receptor activation upregulates the mucus 
genes MUCSAC and MUC2 in human cultured epithelial cells (29). In addition, 
it has been shown that activation of adenosine A1 receptors directly stimulates 
contraction of human bronchial smooth muscle cells (30). These findings may be 
important, since mucus overproduction and airway smooth muscle contraction 
are key clinical features of both asthma and COPD. Another argument compatible 
with a pro-inflammatory effect of adenosine A1 receptors can be derived from 
animal models. In a rabbit model of allergic asthma, the A1 receptor appears to 
be responsible for adenosine-induced bronchoconstriction (31). Interestingly, it 
was found that intragastric administration of the selective adenosine A1 receptor 
antagonist, L-97-1, in allergic rabbits attenuates the early and late asthmatic 
response (32). This is in agreement with a study of Nyce and colleagues. They 
found that EPI-2010, a respirable antisense oligodeoxynucleotide targeted at 
the adenosine A1 receptors in order to reduce their numbers, inhibited the late 
allergic response in rabbits (33). Currently, EPI-2010 is even being investigated in 
clinical trials. It has been shown in phase I/II trials that EPI-2010 is a safe and well 
tolerated drug, although its efficacy in asthma and COPD remains to be proven 
(34-36). However, anti-inflammatory actions of adenosine A1 receptors have 
also been described. Mice that lack the enzyme adenosine deaminase (and are 
therefore unable to break down endogenously formed adenosine) spontaneously 
develop features of asthma including bronchial hyperresponsiveness, enhanced 
mucus secretion, airway eosinophilia, and increased IgE synthesis (37;38). 
These mice exhibited elevated transcript levels for the adenosine A1 receptor 
and the expression was localized predominantly in alveolar macrophages (39). 
Interestingly, it was found that double knockout mice deficient in both adenosine 
deaminase and the adenosine A1 receptor die 15-16 days after birth from an 
inflammatory lung disease that is more severe than that of their age matched 
counterparts deficient only in adenosine deaminase (39). Taken together, these 
findings may suggest an anti-inflammatory effect of macrophages via activation of 
adenosine A1 receptors in this animal model. In agreement with this, it has been 
demonstrated that activation of adenosine receptors on macrophages inhibits the 
production of several pro-inflammatory cytokines (tumor necrosis factor-a (TNF­
a), IL-6, and IL-8) and enhances the release of the anti-inflammatory cytokine 
IL-10 (40-42). In this context, the recent findings of Elzein and colleagues are 
of special interest. They have reported the discovery of a new highly selective 
adenosine A1 receptor agonist, "compound 23" (43). Whether this new drug may 
hold therapeutic potential in asthma and/or COPD remains to be investigated 
in future studies. In conclusion, several pro- and anti-inflammatory effects of 
adenosine A1 receptors have been described in different animal models. Thus 
far, the exact role of adenosine A1 receptors in humans remains to be elucidated. 
Nevertheless, several adenosine A1 receptor agonists and antagonists are 
currently under development. 
Adenosine A2A receptors 
High expression of adenosine A2A receptors has been found in the brain, 
spleen, thymus, mast cells, leukocytes, and platelets, whereas intermediate 
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expression has been found in the heart, lung, and blood vessels (23). Several 
anti-inflammatory actions of adenosine A2A receptors have been described. 
Firstly, it has been shown that activation of adenosine A2A receptors (in contrast 
to adenosine A28 receptors) inhibits the release of histamine and tryptase from 
mast cells (44). Secondly, adenosine A2A receptors reduce chemotaxis, activation 
and degranulation of neutrophils (28;45;46). Thirdly, it has been demonstrated 
that activation of adenosine A2A receptors on monocytes and macrophages 
reduces the production of the pro-inflammatory cytokine IL-12 and enhances 
the anti-inflammatory cytokine IL-10 (41;47;48). Fourthly, it has recently been 
shown in an in vitro model that adenosine A2A receptor activation evokes wound 
closure in bronchial epithelial cells and may thus be involved in the process of 
airway epithelial repair (49). Further support for an anti-inflammatory role of 
adenosine A2A receptors can be derived from a study of Cronstein and colleagues. 
They investigated the anti-inflammatory effects of methotrexate in mice (50). 
It was found that intraperitoneal injection of methotrexate increases adenosine 
concentrations and inhibits neutrophil accumulation. Interestingly, the effect of 
methotrexate was reversed both by adenosine deaminase and by the specific 
adenosine A2A receptor antagonist 3,7-dimethyl-1-propargylxanthine. The results 
of this study suggest that adenosine and adenosine A2A receptors contribute to 
the anti-inflammatory effects of methotrexate in mice. In agreement with this, it 
was demonstrated in mice that low doses of an inflammatory stimulus, causing 
minimal tissue damage in wild-type mice, were sufficient to induce extensive 
tissue damage, higher levels of pro-inflammatory cytokines and eventually death 
in animals lacking the adenosine A2A receptor (51). Furthermore, the adenosine A2A 
receptor agonist CGS21680 inhibited both the early and late inflammatory reaction 
in Brown Norway rats and the magnitude of its effect was similar to that obtained 
with budesonide (52). A recent study in a variety of murine models of asthma and 
COPD has confirmed these beneficial effects of CGS21680. In asthmatic mice, 
CGS21680 inhibited the inflammatory cell influx in bronchoalveolar lavage fluid 
(53). Although adenosine A2A receptor activation did not inhibit the number of 
neutrophils in bronchoalveolar lavage fluid in a mouse model of COPD, neutrophil 
activation was potently inhibited. In addition, the decrease in the number of 
airway macrophages was reversed after treatment with CGS21680. Thus, there 
is extensive evidence for an anti-inflammatory effect of adenosine A2A receptors 
both in humans and in animal models. Therefore, it could be speculated that 
a drug specifically activating the adenosine A2A receptor could have beneficial 
effects in asthma and COPD. Indeed, another adenosine A2A receptor agonist, 
GW328267X, has been developed for use in humans (54). However, it has recently 
been demonstrated in an abstract that treatment with GW326287X 25 µg twice 
daily did not have a protective effect against the late allergic response in asthma 
patients, whereas inhaled fluticasone 250 µg twice did so as a positive control 
(55 ). A possible explanation for the lack of effect could be that GW326287X is 
not entirely selective for the adenosine A2A receptor, but also exhibited some 
inhibitory effect on the adenosine A3 receptor. Possibly, the inhibitory effect on 
adenosine A3 receptors may have counteracted beneficial effects of A2A receptor 
activation. Secondly, it could be argued that the dose of the A2A -agonist used has 
been below the efficacy level. However, higher doses of GW328267X could not 
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be given due to cardiovascular side effects such as an increase in heart rate and 
decrease of blood pressure. Despite these negative results with the inhaled A2A­
agonist GW328267X, we feel that the role of adenosine and adenosine receptors in 
asthma and COPD deserves further study, since it is well possible that modulation 
of adenosine receptor subtypes will have therapeutic implications in asthma and 
COPD. 
Adenosine A28 receptors 
High expression of adenosine A28 receptors has been found in the colon and 
bladder, intermediate expression in the lung and blood vessels, and low expression 
in adipose tissue, adrenal gland, brain, kidney, liver, and pituitary gland (23). In 
addition, expression of adenosine A28 receptors has been identified on mast cells, 
bronchial epithelium, bronchial smooth cells, monocytes, and fibroblasts (56-60). 
Human lung mast cells have been shown to express adenosine A2A and A28 receptors, 
but not adenosine A1 or A3 receptors (61;62). In a study using cultured mast cells 
derived from a patient with mast cell leukaemia (HMC-1 cell line), activation of the 
adenosine A28 receptor alone resulted in mast cell activation (63). Interestingly, it 
has recently been reported that inhalation of AMP, and by implication adenosine, 
induces a rapid (within one hour) inflammatory response with an increase of 
eosinophils into the airways in asthmatic subjects (64). A possible explanation for 
these findings is the release of mast cell derived inflammatory mediators. There 
are various clues that mast cell derived mediators could account for an influx of 
eosinophils into the airways. For example, the proteases tryptase and chymase 
provide a potent stimulus for eosinophil accumulation following injection in the skin 
of guinea pigs (65-67). In addition, inhalation of leukotriene D4 and leukotriene 
E4, which are the major lipoxygenase products of mast cells, is associated with 
increases of eosinophils in sputum and bronchial biopsies (44;68;69). Further, the 
cytokines TNF-a and IL-4, which are stored preformed in the granules of mast 
cells, can facilitate eosinophil recruitment by upregulating adhesion molecules 
(vascular cell adhesion molecule-! and E-selectin) in the endothelial layer of the 
bronchial vasculature (70;71). Another possible explanation for the AMP-induced 
influx of eosinophils into the airways might be that adenosine also exerts an effect 
on A11 A2A' and A3 receptors or on A28 receptors present on other inflammatory 
or structural cells. Indeed several other pro-inflammatory effects of adenosine 
A28 receptors have been described besides mast cell activation. It has been 
shown by Zhong and colleagues that activation of adenosine A28 receptors on 
bronchial smooth muscle cells increases the production of IL-6 and monocyte 
chemotactic protein-! (72). In a more recent study of Zhong and colleagues, 
activation of adenosine A28 receptors on human bronchial epithelial cells evoked 
the release of IL-19. The amount of IL-19 was sufficient to activate the human 
monocyte cell line THP-1 and to increase the release of TNF-a. In turn, TNF-a 
was found to upregulate adenosine A28 receptor expression by threefold. This 
study demonstrates a novel pathway whereby adenosine can initiate and amplify 
inflammatory responses (73). In addition, activation of adenosine A28 receptors 
on human mast cells increases the production of IL-4 and IL-13 and this, in turn, 
promotes IgE production in B lymphocytes (74). Preliminary data from our group 
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show that, conversely, the adenosine A28 receptor was upregulated after stimulation 
of HMC-1 cells with AMP, IL-4, and IL-13. In this way, adenosine may be able to 
amplify allergic inflammatory responses. Taken together, several lines of evidence 
indicate that adenosine A28 receptors contribute to airway inflammation in asthma 
and it is tempting to speculate that a drug specifically inhibiting the adenosine 
A28 receptor may have beneficial effects. In this context, it is of special interest 
that treatment with theophylline, which is also an adenosine A28 antagonist, has 
been shown to reduce airway inflammation both in asthma and in COPD (75;76). 
Although it was originally hypothesized that theophylline acts via inhibition of 
phosphodiesterases, it has been observed that the concentration of theophylline 
required to effectively inhibit phosphodiesterases in vivo was much greater than 
the therapeutic level achieved in humans (77). Since theophylline also inhibits 
adenosine A28 receptors at concentrations likely to occur in vivo, this could well 
be an alternative explanation for its beneficial effects in asthma and COPD (78-
80). Currently, more potent and selective compounds targeting adenosine A28 
receptors are being investigated such as IPDX, CVT-5440, CVT-6883, and 8-
(3-trifluoromethylbenzyl-lH-pyrazol-4-yl)-1,3-dimethylxanthine (81-85). It has 
recently been demonstrated that treatment with the selective adenosine A28 
receptor antagonist, CVT-6883, protects against the development of pulmonary 
inflammation and fibrosis in adenosine deaminase deficient mice (85). Studies 
investigating the therapeutic effects of these new drugs in humans with asthma or 
COPD are now eagerly awaited. Besides an important role in airway inflammation, 
there is now also evidence that adenosine A28 receptors may be involved in the 
process of airway remodeling which occurs in chronic inflammatory lung diseases 
such as asthma and COPD. Thus, it has been shown that activation of adenosine 
A28 receptors induces the release of IL-6 in human lung fibroblasts, which, in turn, 
causes differentiation of these cells into myofibroblasts (59). Interestingly, this 
effect was potentiated by exposure of these fibroblasts to hypoxia. Furthermore, 
it has been shown that activation of adenosine A28 receptors in human lung 
mast cells results in the production of vascular endothelial growth factor 
(VEGF), whereas activation of adenosine A3 receptors results in angiopoietine-
2 mRNA expression (86). These findings suggest that adenosine A28 receptors 
and adenosine A3 receptors are able to act in a cooperative fashion to stimulate 
angiogenesis. It has been shown by Feoktistov and colleagues that the presence 
of hypoxia alters the expression of adenosine receptors in human endothelial 
and smooth muscle cells towards a phenotype with predominantly A28 receptors, 
which concurrently leads to an increase in VEGF production (86). Taken together, 
there is now considerable evidence that adenosine A28 receptors are involved 
both in airway inflammation as well as in the process of airway remodeling. 
Adenosine A3 receptors 
Intermediate expression of adenosine A3 receptors has been found in the 
cerebellum, hippocampus, and lung (71). Low expression has been found in the 
thyroid gland, liver, kidney, heart, and intestine. In addition, adenosine A3 receptors 
have been identified on eosinophils, neutrophils, monocytes, and on mast cells 
of rats, guinea pigs, and mice (26;87). In rats, mice and guinea pigs, adenosine-
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induced mast cell degranulation is mediated by the adenosine A3 receptor (26). 
Several pro-inflammatory effects of adenosine A3 receptor activation have 
been described. It has been shown by Spruntulis and colleagues that inhaled 
adenosine causes a rapid migration of eosinophils and macrophages to the 
airways of sensitized guinea pigs, and this effect was blocked by administration 
of an adenosine A3 receptor antagonist (88). Another argument compatible with 
a pro-inflammatory effect of adenosine A3 receptors can be derived from a study 
of Young and colleagues, investigating adenosine deaminase deficient mice. They 
found an increase in the level of adenosine A3 receptor expression in mucus­
producing cells in the airways (89). Interestingly, the amount of mucus in the 
airways diminished after treatment with the adenosine A3 receptor antagonist 
MRS 1523 (89). In addition, treatment of adenosine deaminase deficient mice 
with a selective adenosine receptor antagonist resulted in a decreased number of 
airway eosinophils, although blood eosinophilia persisted (89). In a later study, the 
degree of mucus production was similar in knockout mice lacking the adenosine 
A3 receptor and wild-type mice suggesting that the adenosine A3 receptor does 
not contribute to mucus production. In contrast to the lack of effect on mucus 
production, the amount of mucus secreted after allergen challenge was increased 
in goblet cells overexpressing the adenosine A3 receptor and absent in knockout 
mice lacking the adenosine A3 receptor (90). Taken together, these findings 
suggest that activation of adenosine A3 receptors may contribute to airway 
obstruction by inducing hypersecretion of mucus on the one hand and migration 
of eosinophils to the airways on the other hand. However, the distribution of 
adenosine A3 receptors in rodents does not match the distribution in humans and 
therefore the clinical relevance of these animal models is unclear. In contrast to 
rats, guinea pigs, and mice adenosine A3 receptors have not been identified on 
human mast cells (89). In humans, adenosine A3 receptors mediate inhibition of 
eosinophil degranulation and chemotaxis when activated (61;91). Other functions 
of A3 receptors involve inhibition of neutrophil degranulation induced by endotoxin 
(92). Further, adenosine A3 receptors suppress the release of TNF-a by human 
monocytes stimulated with endotoxin (47). In conclusion, several pro- and anti­
inflammatory effects of adenosine A3 receptors have been described and the 
exact consequences of adenosine A3 receptor activation in humans remain to be 
further investigated. 
Conclusions 
It is now clear that adenosine and its receptors play an important role in the 
pathophysiology of asthma and COPD. They are involved in the production and 
release of a variety of mediators from inflammatory and structural cells. It has 
even been suggested that the development of drugs which are designed to 
specifically activate or inhibit adenosine receptors could serve as an appropriate 
treatment for asthma and/or COPD. However, in this context there are still several 
difficulties. For example, adenosine receptor subtypes involved in adenosine­
induced bronchoconstriction and inflammatory responses vary among species 
and this makes the clinical relevance of animal models unclear. Thus far, the 
exact distribution and function of the different adenosine receptor subtypes in 
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human airways remains largely unknown and this makes it difficult to establ ish 
which (combination of) receptors should be targeted. Another problem can be 
that adenosine receptors are widely spread in the human body. For this reason 
modulation of specific adenosine receptors could be associated with significant 
side effects, particularly in the central nervous system, heart, and blood vessels. 
Nevertheless, several drugs are currently under development and the results of 
studies investigating their effects are eagerly awaited. 
Reference List 
1)  Cushley MJ, Tattersfield AE, Holgate ST. Inhaled adenosine and guanosine on airway resistance 
in normal and asthmatic subjects. Br J Clin Pharmacol 1983;15(2): 161-5. 
2) Oosterhoff Y, de Jong JW, Jansen MA, Keeter GH, Postma DS. Airway responsiveness to 
adenosine 5'-monophosphate in chronic obstructive pulmonary disease is determined by 
smoking. Am Rev Respir Dis 1993;147(3):553-8. 
3) Church MK, Holgate ST, Hughes PJ. Adenosine inhibits and potentiates IgE-dependent 
histamine release from human basophils by an A2-receptor mediated mechanism. Br J 
Pharmacol 1983 r;80(4):719-26. 
4) Hughes PJ, Holgate ST, Church MK. Adenosine inhibits and potentiates IgE-dependent 
histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. 
Biochem Pharmacol 1984;33(23):3847-52. 
5) Phillips GD, Ng WH, Church MK, Holgate ST. The response of plasma histamine to 
bronchoprovocation with methacholine, adenosine 5'-monophosphate, and allergen in atopic 
nonasthmatic subjects. Am Rev Respir Dis 1990;141(1):9-13. 
6) Polosa R, Ng WH, Crimi N, Vancheri C, Holgate ST, Church MK, Mistretta A. Release of mast­
cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit 
Care Med 1995;151(3 Pt 1):624-9. 
7) Driver AG, Kukoly CA, Metzger WJ, Mustafa SJ. Bronchial challenge with adenosine causes 
the release of serum neutrophil chemotactic factor in asthma. Am Rev Respir Dis 1991;143(5 
Pt 1): 1002-7. 
8) Church MK. The role of basophils in asthma. I .  Sodium cromoglycate on histamine release and 
content. Clin Allergy 1982 y;12(3):223-8. 
9) Crimi N, Palermo F, Oliveri R, Vancheri C, Polosa R, Palermo B, Maccarrone C, Mistretta A. 
Comparative study of the effects of nedocromil sodium (4 mg) and sodium cromoglycate 
(10 mg) on adenosine-induced bronchoconstriction in asthmatic subjects. Clin Allergy 
1988;18(4):367-74. 
10) Phillips GD, Finnerty JP, Holgate ST. Comparative protective effect of the inhaled beta 2-
agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, 
and adenosine 5'-monophosphate in asthma. J Allergy Clin Immunol 1990;85(4):755-62. 
11 )  Phillips GD, Rafferty P, Beasley R, Holgate ST. Effect of oral terfenadine on the bronchoconstrictor 
response to inhaled histamine and adenosine 5'-monophosphate in non-atopic asthma. Thorax 
1987 r;42(12):939-45. 
12) Phillips GD, Holgate ST. The effect of oral terfenadine alone and in combination with 
flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in 
nonatopic asthma. Am Rev Respir Dis 1989;139(2):463-9. 
13) Rutgers SR, Keeter GH, Van Der Mark TW, Postma DS. Protective effect of oral terfenadine 
and not inhaled ipratropium on adenosine 5'-monophosphate-induced bronchoconstriction in 
patients with COPD. Clin Exp Allergy 1999;29(9):1287-92. 
14) Van Den Berge M., Kerstjens HA, Postma DS. Provocation with adenosine 5'-monophosphate 
as a marker of inflammation in asthma, allergic rhinitis and chronic obstructive pulmonary 
disease. Clin Exp Allergy 2002;32(6):824-30. 
15) Driver AG, Kukoly CA, Ali S, Mustafa SJ. Adenosine in bronchoalveolar lavage fluid in asthma. 
Am Rev Respir Dis 1993;148(1):91-7. 
31 
Chapter 2 
16) Varani K, Caramori G, Vincenzi F, Adcock I, Casolari P, Leung E, Maclennan S, Gessi S, 
Morello S, Barnes PJ, Ito K, Chung KF, Cavallesco G, Azzena G, Papi A, Berea PA. Alteration of 
adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med 2006;173(4):398-406. 
17) Ma B, Blackburn MR, Lee CG, Homer RJ, Liu W, Flavell RA, Boyden L, Lifton RP, Sun CX, Young 
HW, Elias JA. Adenosine metabolism and murine strain-specific IL-4-induced inflammation, 
emphysema, and fibrosis. J Clin Invest 2006;116(5):1274-83. 
18) Cushley MJ, Tallant N, Holgate ST. The effect of dipyridamole on histamine- and adenosine­
induced bronchoconstriction in normal and asthmatic subjects. Eur J Respir Dis 1985;67(3): 185-
92. 
19) Yu KH, Luo SF, Liou LB, Wu YJ, Tsai WP, Chen JY, Ho HH. Concomitant septic and gouty 
arthritis--an analysis of 30 cases. Rheumatology (Oxford) 2003;42(9):1062-6. 
20) van Calker D, Muller M, Hamprecht B. Adenosine inhibits the accumulation of cyclic AMP in 
cultured brain cells. Nature 1978;276(5690):839-41. 
21) Rees DA, Scanlon MF, Ham J. Adenosine signalling pathways in the pituitary gland: one ligand, 
multiple receptors. J Endocrinol 2003 J;177(3):357-64. 
22) Razin E, Pecht I, Rivera J. Signal transduction in the activation of mast cells and basophils. 
Immunol Today 1995;16(8):370-3. 
23) Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of 
Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 
2001;53(4):527-52. 
24) Toward TJ, Broadley KJ. Airway reactivity, inflammatory cell influx and nitric oxide in guinea­
pig airways after lipopolysaccharide inhalation. Br J Pharmacol 2000;131(2):271-81. 
25) Thorne JR, Danahay H, Broadley KJ. Analysis of the bronchoconstrictor responses to 
adenosine receptor agonists in sensitized guinea-pig lungs and trachea. Eur J Pharmacol 
1996;316(2-3):263-71. 
26) Fozard JR, Hannon JP. Species differences in adenosine receptor-mediated bronchoconstrictor 
responses. Clin Exp Allergy 2000;30(9) :1213-20. 
27) Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M. The adenosine/neutrophil 
paradox resolved: human neutrophils possess both Al and A2 receptors that promote 
chemotaxis and inhibit 02 generation, respectively. J Clin Invest 1990;85(4):1150-7. 
28) Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G. Neutrophil 
adherence to endothelium is enhanced via adenosine Al receptors and inhibited via adenosine 
A2 receptors. J Immunol 1992;148(7):2201-6. 
29) McNamara N, Gallup M, Khong A, Sucher A, Maltseva I, Fahy J, Basbaum C. Adenosine up­
regulation of the mucin gene, MUC2, in asthma. FASEB J 2004;18(14): 1770-2. 
30) Ethier MF, Madison JM. Adenosine Al Receptors Mediate Mobilization of Calcium in Human 
Bronchial Smooth Muscle Cells. Am J Respir Cell Mol Biol 2006;18: 1770-2. 
31)  el Hashim A, D'Agostino B,  Matera MG, Page C. Characterization of  adenosine receptors 
involved in adenosine-induced bronchoconstriction in allergic rabbits. Br J Pharmacol 
1996;119(6):1262-8. 
32) Obiefuna PC, Batra VK, Nadeem A, Borron P, Wilson CN, Mustafa SJ. A novel Al adenosine 
receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy­
ethyl)-amino]- ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to 
house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther 2005;315(1):329-
36. 
33) Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 
1997;385(6618):721-5. 
34) Sandrasagra A, Leonard SA, Tang L, Teng K, Li Y, Ball HA, Mannion JC, Nyce JW. Discovery 
and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid 
Drug Dev 2002;12(3): 177-81 .  
35) Nyce J .  Respirable antisense oligonucleotides: a new, third drug class targeting respiratory 
disease. Curr Opin Allergy Clin Immunol 2002;2(6):533-6. 
32 
Adenosine receptors in the treatment of asthma and COPD 
36) Ball HA, Van Scott MR, Robinson CB. Sense and antisense: therapeutic potential of 
oligonucleotides and interference RNA in asthma and allergic disorders. Clin Rev Allergy 
Immunol 2004;27(3):207-17. 
37) Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR. Adenosine-dependent 
airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient 
mice. J Immunol 2001;167(8) :4676-85. 
38) Zhong H, Chunn JL, Volmer JB, Fozard JR, Blackburn MR. Adenosine-mediated mast cell 
degranulation in adenosine deaminase-deficient mice. J Pharmacol Exp Ther 2001;298(2):433-
40. 
39) Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A protective role 
for the Al adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 
2005;115(1):35-43. 
40) Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-alpha 
expression by adenosine: role of A3 adenosine receptors. J Immunol 1996;156(9):3435-42. 
41) Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists 
differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages 
and in endotoxemic mice. J Immunol 1996;157(10):4634-40. 
42) Le Moine 0, Stordeur P, Schandene L, Marchant A, de Groote D, Goldman M, Deviere J. 
Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996;156(11):4408-
14. 
43) Elzein E, Kalla R, Li X, Perry T, Marquart T, Micklatcher M, Li Y, Wu Y, Zeng D, Zablocki J. 
N(6)-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine Al 
receptor agonists. Bioorg Med Chem Lett 2007;17(1) :161-6. 
44) Suzuki H, Takei M, Nakahata T, Fukamachi H. Inhibitory effect of adenosine on degranulation 
of human cultured mast cells upon cross-linking of Fe epsilon RI. Biochem Biophys Res 
Commun 1998;242(3):697-702. 
45) Wollner A, Wollner S, Smith JB. Acting via A2 receptors, adenosine inhib its the upregulation 
of Mac-1 (Cdllb/CD18) expression on FMLP-stimulated neutrophils. Am J Respir Cell Mal Biol 
1993;9(2) :179-85. 
46) Fredholm BB, Zhang Y, van dP, I. Adenosine A2A receptors mediate the inhib itory effect 
of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes. 
Naunyn Schmiedebergs Arch Pharmacol 1996;354(3):262-7. 
47) Le Vraux V, Chen YL, Masson I, De Sousa M, Giraud JP, Florentin I, Chauvelot-Moachon 
L. Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sci 
1993;52(24):1917-24. 
48) Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabo C. 
Adenosine inhib its IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent 
and independent mechanisms. FASEB J 2000;14(13):2065-74. 
49) Allen-Gipson DS, Wong J, Spurzem JR, Sisson JH, Wyatt TA. Adenosine A2A receptors 
promote adenosine-stimulated wound healing in bronchial epithelial cells. Am J Physiol Lung 
Cell Mal Physiol 2006;290(5):L849-L855. 
50) Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function 
by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 
1991;88(6):2441-5. 
51) Ohta A, Sitkovsky M .  Role of G-protein-coupled adenosine receptors in downregulation of 
inflammation and protection from tissue damage. Nature 2001;414(6866):916-20. 
52) Fozard JR, Ellis KM, Villela Dantas MF, Tigani B, Mazzoni L. Effects of CGS 21680, a selective 
adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 
2002;438(3):183-8. 
53) Bonneau O, Wyss D, Ferretti S, Blaydon C, Stevenson CS, Trifilieff A. Effect of adenosine A2A 
receptor activation in murine models of respiratory disorders. Am J Physiol Lung Cell Mal 
Physiol 2006;290(5):L1036-L1043. 
54) Holgate ST. The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor 
as a novel therapeutic target in asthma. Br J Pharmacol 2005;145(8): 1009-15. 
33 
Chapter 2 
55) Luijk B, Van Den Berge M, Kerstjens HA, Postma DS, Cass L, Sabin A, Lammers JW. Effect of 
an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response. Allergy 
2008;63:75-80. 
56) Clancy JP, Ruiz FE, Sorscher EJ. Adenosine and its nucleotides activate wild-type and R117H 
CFTR through an A2B receptor-coupled pathway. Am J Physiol 1999;276(2 Pt 1):C361-C369. 
57) Marquardt DL, Walker LL, Heinemann S. Cloning of two adenosine receptor subtypes from 
mouse bone marrow-derived mast cells. J Immunol 1994;152(9):4508-15. 
58) Zhang JG, Hepburn L, Cruz G, Borman RA, Clark KL. The role of adenosine A2A and 
A2B receptors in the regulation of TNF-alpha production by human monocytes. Biochem 
Pharmacol 2005;69(6):883-9. 
59) Zhong H, Belardinelli L, Maa T, Zeng D. Synergy between A2B adenosine receptors and 
hypoxia in activating human lung fibroblasts. Am J Respir Cell Mal Biol 2005;32(1):2-8. 
60) Mundell SJ, Olah ME, Panettieri RA, Benovic JL, Penn RB. Regulation of G protein-coupled 
receptor-adenylyl cyclase responsiveness in human airway smooth muscle by exogenous and 
autocrine adenosine. Am J Respir Cell Mol Biol 2001;24(2):155-63. 
61) Walker BA, Jacobson MA, Knight DA, Salvatore CA, Weir T, Zhou D, Bai TR. Adenosine A3 
receptor expression and function in eosinophils. Am J Respir Cell Mal Biol 1997;16(5):531-7. 
62) Marquardt R, Fischer J, Kustner W. Effect of arterial hypoxia and acidosis on fibrillation 
threshold in the cat heart in vivo. Z Kardiol 1976;65(7):585-9. 
63) Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-a secretion in human 
mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 
1995 r;96(4):1979-86. 
64) Van den Berge M, Kerstjens HA, de Reus DM, Koeter GH, Kauffman HF, Postma DS. Provocation 
with adenosine 5'-monophosphate, but not methacholine, induces sputum eosinophilia. Clin 
Exp Allergy 2004;34(1):71-6. 
65) Walls AF, He S, Teran LM, Buckley MG, Jung KS, Holgate ST, Shute JK, Cairns JA. Granulocyte 
recruitment by human mast cell tryptase. Int Arch Allergy Immunol 1995;107(1-3):372-3. 
66) He S, Walls AF. Human mast cell chymase induces the accumulation of neutrophils, eosinophils 
and other inflammatory cells in vivo. Br J Pharmacol 1998;125(7) :1491-500. 
67) Compton SJ, Cairns JA, Holgate ST, Walls AF. Interaction of human mast cell tryptase 
with endothelial cells to stimulate inflammatory cell recruitment. Int Arch Allergy Immunol 
1999;118(2-4):204-5. 
68) Gauvreau GM, Parameswaran KN, Watson RM, O'Byrne PM. Inhaled leukotriene E(4), but not 
leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J 
Respir Crit Care Med 2001;164(8 Pt 1): 1495-500. 
69) Mulder A, Gauvreau GM, Watson RM, O'Byrne PM. Effect of inhaled leukotriene D4 on airway 
eosinophilia and airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care 
Med 1999;159(5 Pt 1) :1562-7. 
70) Hirata N, Kohrogi H, Iwagoe H, Goto E, Hamamoto J, Fujii K, Yamaguchi T, Kawano 0, Ando 
M. Allergen exposure induces the expression of endothelial adhesion molecules in passively 
sensitized human bronchus: time course and the role of cytokines. Am J Respir Cell Mol Biol 
1998;18(1):12-20. 
71)  Blease K, Seybold J, Adcock IM, Hellewell PG, Burke-Gaffney A. Interleukin-4 and 
lipopolysaccharide synergize to induce vascular cell adhesion molecule-1 expression in human 
lung microvascular endothelial cells. Am J Respir Cell Mal Biol 1998;18(5):620-30. 
72) Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I, Zeng D. A2B adenosine receptors 
increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 
2004;30(1):118-25. 
73) Zhong H, Wu Y, Belardinelli L, Zeng D. A2B Adenosine Receptors Induce IL-19 from Bronchial 
Epithelial Cells and Results in TNF-{alpha} Increase. Am J Respir Cell Mal Biol 2006;35(5):587-
92. 
74) Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, Feoktistov I. Adenosine-activated 
mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 
cytokines IL-4 and IL-13 with implications for asthma. J Immunol 2004;172(12):7726-33. 
34 
Adenosine receptors in the treatment of asthma and COPD 
75) Lim S, Tomita K, Carramori G, Jatakanon A, Oliver B, Keller A, Adcock I, Chung KF, Barnes PJ. 
Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild 
asthma. Am J Respir Crit Care Med 2001;164(2):273-6. 
76) Morali T, Yilmaz A, Erkan F, Akkaya E, Ece F, Baran R. Efficacy of inhaled budesonide and oral 
theophylline in asthmatic subjects. J Asthma 2001;38(8):673-9. 
77) Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low­
dose oral theophylline in atopic asthma. Lancet 1994;343(8904): 1006-8. 
78) Feoktistov I, Polosa R, Holgate ST, Biaggioni I. Adenosine A2B receptors: a novel therapeutic 
target in asthma? Trends Pharmacol Sci 1998;19(4): 148-53. 
79) Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse Ml Comparative 
pharmacology of human adenosine receptor subtypes - characterization of stably transfected 
receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 1998;357(1):1-9. 
80) Evans DJ, Taylor DA, Zetterstrom 0, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low­
dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate 
asthma. N Engl J Med 1997;337(20):1412-8. 
81) Feoktistov I ,  Garland EM, Goldstein AE, Zeng D, Belardinelli L ,  Wells JN, Biaggioni I. Inhibition 
of human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-
isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol 2001;62(9):1163-73. 
82) Fozard JR, Baur F, Wolber C. Antagonist pharmacology of adenosine A2B receptors from rat, 
guinea pig and dog. Eur J Pharmacol 2003;475(1-3):79-84. 
83) Zablocki J, Kalla R, Perry T, Palle V, Varkhedkar V, Xiao D, Piscopio A, Maa T, Gimbel A, Hao 
J, Chu N, Leung K, Zeng D. The discovery of a selective, high affinity A2B adenosine receptor 
antagonist for the potential treatment of asthma. Bioorg Med Chem Lett 2005;15(3):609-12. 
84) Kalla RV, Elzein E, Perry T, Li X, Palle V, Varkhedkar V, Gimbel A, Maa T, Zeng D, Zablocki 
J. Novel 1,3-disubstituted 8-(1-benzyl-lH-pyrazol-4-yl) xanthines: high affinity and selective 
A2B adenosine receptor antagonists. J Med Chem 2006;49(12):3682-92. 
85) Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, 
Blackburn MR. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary 
inflammation and injury. J Clin Invest 2006;116(8):2173-82. 
86) Feoktistov I, Ryzhov S, Zhong H, Goldstein AE, Matafonov A, Zeng D, Biaggioni I .  Hypoxia 
modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B 
angiogenic phenotype. Hypertension 2004;44(5) :649-54. 
87) Spicuzza L, Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur 
J Pharmacol 2006;533(1-3):77-88. 
88) Spruntulis LM, Broadley KJ. A3 receptors mediate rapid inflammatory cell influx into the l ungs 
of sensitized guinea-pigs. Clin Exp Allergy 2001;31(6):943-51. 
89) Young HW, Molina JG, Dimina D, Zhong H, Jacobson M, Chan LN, Chan TS, Lee JJ, Blackburn 
MR. A3 adenosine receptor signaling contributes to airway inflammation and mucus production 
in adenosine deaminase-deficient mice. J Immunol 2004;173(2):1380-9. 
90) Young HW, Sun CX, Evans CM, Dickey BF, Blackburn MR. A3 Adenosine Receptor Signaling 
Contributes to Airway Mucin Secretion Following Allergen Challenge. Am J Respir Cell Mol Biol 
2006;35(5):549-558. 
91)  Knight D, Zheng X, Rocchini C,  Jacobson M, Bai T, Walker B. Adenosine A3 receptor stimulation 
inhibits migration of human eosinophils. J Leukoc Biol 1997;62(4):465-8. 
92) Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of 





Effects of IL-4 and IL-13 on adenosine receptor 
expression and responsiveness of the human mast cel l  
l ine 1 
Mieke Versluis1,2, Dirkje S. Postma2, Wim Timens1, Machteld N. Hylkema1 
1 Department of Pathology and Laboratory Medicine, 2 Department of Pulmonology, 
University Medical Center Groningen, University of Groningen, Groningen, The 
Netherlands 
International Immunopharmacology 2008; 8: 866-873 
Chapter 3 
Abstract 
Background: Inhalation of adenosine-5'-monophosphate (AMP) causes 
bronchoconstriction in asthma but not in healthy subjects. Bronchoconstriction 
upon AMP inhalation is thought to occur by histamine release and subsequent 
binding to receptors on airway smooth muscle cells. 
Methods: To explain enhanced sensitivity to AMP in asthma, mast cell expression 
of the adenosine A2A and A26 receptors and histamine release were measured 
after incubation of human mast cell line 1 (HMC-1) cells with AMP and the non­
specific adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) for 
1.5 and 6 hours. To establish a Thelper-2 environment resembling the asthma 
phenotype, HMC-1 cells were additionally cultured with IL-4 and IL-13 alone or 
stimulated with the combination of both cytokines and AMP and NECA. To study 
effects of prolonged presence of the inflammatory environment, the cells were 
pre-incubated overnight (18 h) with IL-4 and IL-13 and additionally stimulated 
with AMP and NECA for 1.5 or 6h. 
Results: AMP and NECA hardly affected adenosine receptor expression but 
increased IL-8 secretion. Incubation with IL-4 and IL-13 for 6 hours increased 
adenosine A2A receptor expression and histamine secretion, but decreased IL-8 
secretion. The combination of IL-4, IL-13, and AMP/NECA for 6 hours increased 
A26 receptor expression and IL-8 secretion. Overnight stimulation with IL-4, IL-13 
and subsequent stimulation with AMP/NECA for 1.5 h decreased A2AR expression 
which was accompanied by increased histamine secretion. 
Conclusion: These results suggest a role for decreased A2AR expression in 
enhanced adenosine responsiveness as observed in asthma. 
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Introduction 
Inhalation of adenosine or its more stable form adenosine-5'-monophosphate 
(AMP) causes bronchoconstriction in asthma but not in healthy subjects (1). 
In addition, increased concentrations of adenosine have been found at sites of 
inflammation and in bronchoalveolar lavage fluid of asthma patients (2). For these 
reasons it is believed that adenosine and adenosine receptors have an important 
role in asthma (3). Adenosine plays a role in the energy metabolism of the cell, 
being formed during dephosphorylation of ATP (� ADP � AMP � adenosine). 
It can cause the release of inflammatory mediators after binding to adenosine 
receptors on inflammatory cells (e.g. mast cells). 
Adenosine receptors are G-protein coupled receptors and four of these receptors 
have been described; Al' A2A, A26 and A3 (4). The adenosine A2A and A26 receptors 
are Gs -protein coupled receptors (5). After binding of adenosine they will activate 
adenylyl cyclase, which results in an increased production of cyclic AMP that will 
inhibit activation of the cell. An important difference between adenosine A2A and 
A26 receptors is the ability of adenosine A26 receptors to additionally couple to 
Gq -proteins (6). This then results in activation of phospholipase C which splices 
phosphatidylinositol-4,5 bisphosphate (PIP 2) in diacylglycerol (DAG) and inositol 
triphosophate (IP3).  DAG activates protein kinase C and IP3 activates calcium 
channels, actions necessary for the fusion of granules of mast cells with the 
plasma membrane (7,8). Binding of adenosine to the low-affinity adenosine A26 
receptor causes degranulation of mast cells (3,9) resulting in histamine release, 
which in turn may induce bronchoconstriction by binding to histamine receptors 
on airway smooth muscle cells. In contrast, binding of adenosine to the high­
affinity A2A receptor results in suppression of histamine release from mast cells 
(3,10-12). 
IL-4 and IL-13, typical Th2 cytokines, are present in higher concentrations after 
allergen challenge in lungs of asthma patients compared to non-asthmatic 
subjects (13). Both cytokines are produced by Th2 cells and mast cells and play 
an important role in allergic inflammation, such as isotype switching of B cells to 
IgE synthesis (14). Both IL-4 and IL-13 can cause mast cell activation in vivo (15), 
and in vitro (16). 
In this study we were interested in the relationship between adenosine 
responsiveness of mast cells and asthma. Therefore, we investigated the effects 
of IL-4 and IL-13 on in vitro mast cell function and adenosine receptor expression. 
Since it is difficult to obtain mast cells from asthma patients, the human mast 
cell line 1 (HMC-1) was used and cultured in the presence of IL-4 and IL-13. The 
HMC-1 mast cell line was established from peripheral blood of a patient with mast 
cell leukaemia (17). These cells have a low expression of the high affinity IgE 
receptor, but show expression of the adenosine A2A' A26, and A3 receptors (18,19) 
and express functional receptors for both IL-4 and IL-13 (20). These features make 
this HMC-1 cell a suitable tool to study the effects of adenosine and Th2 cytokines 
on mast cells. A higher expression of the A26R over A2AR might explain increased 
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AMP responsiveness in asthma. We hypothesized that culturing of HMC-1 cells in 
a Th2 environment (IL-4, IL-13), like it is present in airways of asthma patients, 
would increase A28R and decrease the A2AR expression. 
Material and methods 
HMC-1 cell line 
The leukemic mast cell line HMC-1 (a generous gift from doctor J.H. Butterfield, 
Mayo Clinic, Rochester MN) was maintained in suspension culture at a density 
between 0.3 and 1 x 106 cells/ml by culturing in Iscove's Modified Dulbecco's 
Medium (IMDM, Gibco®, Paisley, UK) supplemented with 10 % (v/v) heat­
inactivated fetal calf serum (FBS; Gibco®), 1.23 mM L-glutamine (BioWhittaker, 
Verviers, Belgium), 50 µM B-mercaptoethanol (Gibco®), 5 µg/ml apo-transferrin 
(Sigma, St. Louis, USA), 100 U/ml penicillin (BioWhittaker), and 100 µg/ml 
streptomycin (BioWhittaker). Cells were kept under humidified atmosphere of 
air/CO2 (19:1) at 37
°C. 
Stimulation with AMP and NECA 
To stimulate the cells via the adenosine receptors, 5'-adenosinemonophosphate 
(AMP) and the non-specific adenosine receptor agonist 5'-N-ethylcarboxamido­
adenosine (NECA) were added to the culture medium of the cells. HMC-1 cells 
(1 x 106 cells/ml, n = 7) were cultured either with AMP (0.1 µM, Sigma), with 
NECA (1 µM, Sigma), or with the combination AMP/NECA (both dissolved in IMDM, 
optimal concentrations obtained from previous experiments, data not shown). 
Cells were incubated for 1.5 or 6 hours under humidified atmosphere of air/CO2 
(19:1) at 37°C. At the end of the incubation periods cells were harvested and 
culture supernatants were collected by centrifugation at 500 x g for 5 minutes 
at 4°C. Cells were used for flow cytometric analysis for adenosine receptor 
expression and supernatants were used for histamine and IL-8 secretion. 
Stimulation with IL-4 and IL-13 
To investigate whether cytokines that are increased in asthma patients alter 
adenosine receptor expression and cell degranulation, HMC-1 cells (1 x 106 
cells/ml, n = 8) were cultured either with recombinant human IL-4 (10 ng/ml, 
Strathmann Biotec AG, Hamburg, Germany), with recombinant human IL-13 (20 
ng/ml, PeproTech Inc, Rocky Hill, USA) or with the combination of both IL-4 and 
IL-13. These cytokines were added in optimal concentrations as deduced from 
previous experiments (data not shown). Furthermore, a combination of IL-4/IL-13 
and AMP/NECA (in previously mentioned concentrations) was added in a separate 
experiment. The choice to stimulate HMC-1 cells with the combination of AMP 
and NECA in stead of AMP alone was based on data from the literature in which 
IL-8 was the read-out parameter, produced upon activation of the A28R (21,19). 
Cells were incubated for 1.5 or 6 hours under humidified atmosphere of air/CO2 
(19:1) at 37°C. At the end of the incubation periods cells were harvested and 
treated as mentioned above. 
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Overnight (18 h) incubation with IL-4/IL-13 (with and without AMP/ 
NECA) 
To establish an asthmatic environment for a longer time period, IL-4 and IL-13 
were added overnight to the cultures before stimulation with AMP/NECA. HMC-1 
cells (1 x 106 cells/ml, n = 8) were incubated overnight (18 h) with and without 
the combination of IL-4/IL-13. In addition, cells were stimulated by adding the 
combination AMP/NECA (0. 1  and 1.0 µM respectively) for 1 .5  or 6 hours. Cells 
were incubated under humidified atmosphere of air/CO2 (19:1) at 37
°C. At the end 
of the incubation periods cells were harvested and treated as mentioned above. 
This experiment was repeated (n = 4) with an extra wash step between the 
overnight pre-incubation with IL-4 and IL-13 and the stimulation of AMP/NECA. 
After centrifugation of the cell suspensions, cel l  pellets were resuspended in 
fresh HMC-1 medium with addition of the stimulants. Supernatants were used for 
histamine measurement only. 
Pre-incubation with theophylline 
To investigate whether histamine secretion following AMP/NECA stimulation could 
be inhibited by an antagonist for the adenosine A26 receptor, HMC-1 cells were 
pre-incubated for 30 minutes with 150µM theophyl l ine (non-selective adenosine 
receptor antagonist with the highest affinity for A26R, Sigma) prior to a 6-hour 
stimulation with IL-4/IL-13 and/or AMP/NECA. Cells were incubated under humidified 
atmosphere of air/CO2 (19:1) at 37
°C. At the end of the incubation period cel ls 
were harvested and supernatant was stored for histamine measurements. 
Flow cytometric analysis 
To investigate adenosine receptor expression on HMC-1 cells, flow cytometric 
analysis was performed. Cells were stained with the primary antibodies rabbit­
anti-canine A2AR (1:15, cross-reactivity with human) and rabbit-anti-human A26R 
(1:20), both from Alpha Diagnostic International (San Antonio, USA). The secondary 
antibody used was fluorescein isothiocyanate (FITC) conjugated goat-anti-rabbit 
(1:25, Becton Dickinson, Franklin Lakes, USA) . Cells were resuspended in FACS 
lysing solution (Becton Dickinson). Cells (2 x 104 events) were analyzed using an 
Epics® El ite flow cytometer (Coulter, Fullerton, USA) and raw data ana lysis was 
performed with FlowJo (TreeStar, San Carlos, CA). The gates to calculate the MFI 
(mean fluorescence intensity) of FITC positive cells were set in the FITC histogram 
of unstained cells, the gate was set at the point were less than 1% of the cells 
was FITC positive, and copied to all other samples. In the first experiment an 
isotype control was added (normal rabbit IgG), and its histogram was similar to 
unstained cells. Data is presented as a percentage of control (no stimulation), 
which was set at 100%. 
Histamine and IL-8 measurement 
Histamine content of the culture supernatants was measured using a Histamine 
ELISA (IBL, Hamburg, Germany). IL-8 was measured using a Pel iKine Compact™ 
human IL-8 ELISA kit from Sanquin Reagents (Amsterdam, The Netherlands). For 
IL-8, all values were corrected for their control, which was set at 100%. Measured 




All data (except histamine) were corrected for the control samples (no stimulation, 
but incubated during the same time) of the respective day of stimulation (control 
= 100%). Statistics were performed using a non-parametric Mann-Whitney U 








� 1 25 
; 1 00 
75 
Control 
1 .5h incubation 
AMP NECA AMP/NECA 









20�- - - - - - - - - -
1250 
� 1 000 
C: 
] 750 





















so�---- - - ---- -
Control AMP 
Control AMP 








* * .. 
NECA AMP/NECA 
Figure 1. Adenosine A2A (A) and A28 (B) receptor expression, histamine release (C) and IL-8 
secretion by H MC-1 cells after incubation with AMP and/or NECA for 1 .5  hours (left panels) and 6 
hours (right panels). All values (except histamine) are corrected for the control which was set at 
100%. Horizontal bars represent median values. * p < 0.05 vs. control. # p = 0.05 vs. control. 
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Results 
Effects of AMP and NECA 
AMP and NECA, or their combination induced no changes in the adenosine A2A 
and A26 receptor expression when compared to control (figure lA and 1B). 
There was some basal histamine release, and stimulation of HMC-1 cel ls with 
AMP/NECA for 1 .5h enhanced histamine release (p=0.05). 
To compare our results with those described in the literature where IL-8 was 
described as a marker for HMC-1 activation via A26R (19,21), we measured IL-
8 in our supernatants. Incubation with NECA or the combination of AMP and 
NECA significantly enhanced IL-8 secretion by HMC-1 cells after 1.5 and 6 hour 
incubation (p<0.05, figure lD), no synergistic effect of AMP and N ECA was 
observed. Incubation with AMP for 6 h increased IL-8 secretion slightly, but 
significantly. 
Effects of IL-4 and IL-13 
Stimulation with AMP and NECA induced minimal changes in adenosine receptor 
expression. Therefore, HMC-1 cells were incubated with IL-4 and IL-13, cytokines 
that are known to be present in asthmatic lungs, to assess their effect on 
adenosine receptor expression and responsiveness. IL- 4 and IL-13 separately 
had no effect on the expression of both adenosine A2 receptors (figure 2A en 
B). In contrast, we found a modest increased adenosine A2AR expression after 
1 .5  and 6h (p<0.05) and of A26R expression after 6h (p<0.05) when cells were 
stimulated with the combination of IL-4 and IL-13. A26R expression was increased 
after 6h of incubation with the combination of IL-4/IL-13 and AMP/NECA (p<0.05, 
figure 2A and 2B). Increased histamine release was found after incubation with 
IL:-4 or the combination of IL-4 and IL-13 for 1 .5h and 6h and the combination of 
IL-4/IL-13/AMP/NECA for 1 .5h (p<0.05, figure 2C). 
In contrast to the increased IL-8 secretion after incubation with AMP and NECA, 
IL-8 secretion was significantly decreased after incubation with IL-4 and IL-13 
alone for both 1 .5  and 6h and the combination of IL-4/ IL-13 for 6h (p<0.05, figure 
2D). When cel ls were incubated with the combination of IL-4/IL-13/AMP/NECA, 
IL-8 secretion increased significantly when compared to control and IL-4/IL-13 
(p<0.05). 
Effects of overnight incubation with IL-4 and IL-13 
To further enhance adenosine responsiveness with respect to AR expression 
and histamine release, HMC-1 cells were incubated with IL-4 and IL-13 for a 
longer period (18h, overnight), and subsequently stimulated with AMP/NECA for 
1 .5 or 6h. We found down regulated A2AR expression after overnight IL-4/IL-13 
incubation and subsequent AMP/NECA stimulation for 1 .5  (figure 3A, p<0.05) 
with no effect on A26R expression (figure 3B). However, the A2AR/A26R ratio was 
significantly (p<0.05) decreased after overnight incubation with IL-4/IL-13 and 
subsequent stimulation with AMP/NECA for 1.5 or 6h, being (median (range)) 0.90 
(0.85-1.07) and 0 .89 (0.54-0.98) respectively. This was accompanied by enhanced 
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Figure 2. Adenosine A2A (A) and A28 (B) receptor expression, histamine release (C) and IL-8 
secretion (D) after incubation of HMC-1 cells with IL-4, IL-13, IL-4/IL-13 and IL-4/IL-13/AMP/NECA 
for 1 .5  hours (left panels) and 6 hours (right panels). All values (except histamine) are corrected 
for the control which was set at 100%. Horizontal bars represent median values. * p < 0.05 vs. 
control, # p < 0.05 vs. IL-4/IL-13. 
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Enhanced histamine release was also found after stimulation with IL-4/IL-13 alone 
(p<0.05, figure 3C). Overnight IL-4/IL-13 incubation decreased IL-8 production 
when compared to control (p<0.05, figure 3D), as well as AMP/NECA induced IL-8 
production (p<0.05, figure 3D). 
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Figure 3. Adenosine A2A (A) and A28 (B) receptor expression, histamine release (C), and IL-
8 secretion (D) after overnight incubation of HMC-1 cells with IL-4/IL-13, and subsequently 
AMP/NECA stimulation for 1 .5 hours (left panels) and 6 hours (right panels). All values (except 
histamine) are corrected for the control which was set to 100%. Horizontal bars represent median 
values. * p < 0.05 vs. control, oo p < 0.05 vs. overnight IL-4/IL-13, # p < 0.05 vs. AMP/NECA. 
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Figure 4. Histamine secretion by HMC-
1 cells pre-incubated for 30 minutes 
with theophylline and subsequently 
stim ulated for 6 hours with IL-4/IL-13 
and AMP/NECA. Data expressed as 
mean ± SEM. * p < 0.05 vs. IL-4/IL:-
13/AMP/NECA . 
In order to confirm a role for the adenosine A28 receptor in histamine secretion 
by HMC-1 cells, cells were incubated with theophyll ine prior to stimulation. As 
shown in figure 4, theophyl l ine protected against IL-4/IL-13/AMP/NECA-induced 
h istamine secretion. Theophyl l ine alone had no effect on viabil ity and histamine 
release of HMC-1 cells (data not shown). 
Discussion 
In order to shed more l ight on the enhanced adenosine responsiveness of asthma 
patients (1,22,23), we studied adenosine receptor expression and responsiveness 
of HMC-1 mast cells in relation to various culture conditions in vitro. Most 
i nterestingly, we found that increased levels of histamine were released when 
HMC-1 cells were cultured in the presence of cytokines that are important in the 
pathogenesis of asthma, i.e. IL-4 and IL-13, in combination with AMP and NECA. 
The highest increase in histamine release was found when cel ls were cultured for 
a long period with IL-4 and IL-13, i .e. overnight (18 h), fol lowed by AMP/NECA. 
This enhanced histamine release after overnight stimulation was accompanied by 
a decrease in  the A2A/A28 receptor expression ratio on the cell, due to a decreased 
A2AR expression. Since the A28 receptor is involved in NECA-induced mast cel l  
degranulation (21) whereas the A2A receptor i s  involved in inhibition of the release 
of histamine from mast cells (10,24), the ratio between the two receptors may 
g ive additional information on the sensitivity of HMC-1 cells for AMP/NECA and 
IL-4/IL-13 stimulation. Although no data in  the l iterature are available on the A2AR/ 
A28R ratio of mast cells in asthma, a shift in the A2A /A28 receptor ratio towards 
the A28R may explain the enhanced sensitivity of asthma patients to inhaled AMP, 
caused by a decreased suppression of degranulation by the A2AR. 
Enhanced histamine release was also found, albeit to a smaller extent, when cells 
were cultured with the combination of AMP and NECA (1.Sh). Our results support 
earlier data, showing that adenosine alone, but also NECA, causes an enhanced 
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histamine release from lavage mast cel ls in 37 of 54 asthma patients (25) . This 
could be inhibited after pre-incubation of lavage mast cells with an adenosine 
receptor antagonist. 
We showed that theophyl l ine reduced the IL-4/IL-13/AMP/NECA-induced histamine 
release. It has been described that theophyl l ine inhibits phosphodiesterases, 
thereby increasing intracellular cAMP levels of mast cells which results in inhibition 
of mediator release (26,27) . It has been suggested that degranulation of mast 
cells upon stimulation with AMP or NECA is mediated by A28R on HMC-1 cel ls .  
Since we show that theophyl l ine inhibits histamine secretion upon IL-4/IL-13/AMP/ 
NECA stimulation, it is l ikely that theophyll ine antagonizes adenosine receptors. 
The effect of IL-4 or IL-13 on histamine release, adenosine responsiveness, and 
adenosine receptor expression of HMC-1 cells has not been described before. It 
is known that both cytokines can induce airway hyperresponsiveness within 6 h 
after administration to airways of na"ive (unstimulated) mice (28). IL-4 has been 
described to enhance IgE/anti-IgE antibody-induced histamine release in human 
cultured mast cells that were generated from umbil ical cord blood mononuclear 
cells (29). Recently, Ma et al. (30) showed in IL-4 transgenic mice that IL-4 
stimulates tissue adenosine accumulation, inhibits adenosine deaminase (the 
enzyme responsible for adenosine breakdown to inosine) activity, and enhances 
the expression of the adenosine Av A281 and A3 receptors in C57BL/6 mice. These 
results clearly confirm the connection between IL-4 and adenosine receptor 
expression as found in our study, although Ma et al. did not investigate the 
expression site of the adenosine receptors. The same study also showed that IL-
4 differentially regulated adenosine metabolism and receptor expression in two 
different mouse strains, demonstrating that genetic factors may have profound 
influences on effects of IL-4. Thus d ifferences in the regulation of adenosine 
metabolism and receptor expression may contribute to differences in adenosine 
responsiveness. 
In a study using IL-13 transgenic mice, IL-13 caused striking changes in  
adenosine receptor mRNA expression of the lung, the A2A receptor expression 
being unaltered or decreased and A1, A28, and A3 receptors being increased in 
their expression (31). These results clearly suggest a relation between IL-13 and 
adenosine receptor expression, but as for IL-4, expression sites of the receptors 
were not investigated. 
With respect to the effect of IL-4/IL-13 on adenosine receptor expression in this 
study, overnight stimulation with IL-4/IL-13 in combination with AMP/NECA for 1 .5h 
downregulated A2AR expression (figure 3), accompanied by enhanced histamine 
release. This finding was not seen after stimulation with AMP/NECA alone 
(figure 1), suggesting that IL-4/IL-13 interacts with the mast cell and potentiates 
adenosine-induced mast cell activation, by downregulation of the A2AR. 
We measured IL-8 next to histamine since IL-8 is produced by HMC-1 cells upon 
adenosine stimulation (18,19,21). IL-8 is a member of the CXC chemokine fami ly 
involved in recruitment of leukocytes to the site of inflammation (32). Unstimulated 
HMC-1 cells secrete a very low amount of IL-8 but its production is rapidly induced 
by stimul i l ike e.g. adenosine (19,21) .  The primary adenosine receptor involved is 
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l ikely the A28 receptor since agonists (e.g. NECA) with the strongest binding to the 
A28 receptor were the best stimulators of IL-8 release, and furthermore adenosine­
mediated IL-8 production can be inhibited by the competitive A28R antagonists 
theophyll ine (non-selective) and enprofylline (19,21,33). Our data regarding IL-8 
secretion upon AMP or NECA stimulation are in l ine with this. Interestingly, IL-8 
production was also inhibited after culturing of HMC-1 cells in the presence of 
IL-4 and IL-13 or their combination (figure 2 and 3). This is compatible with the 
following observations. IL-13 inhibits IL-8 release in resting synovial fibroblasts 
(34) and IL-4 decreases TNF-a-induced IL-8 mRNA expression in the keratinocyte 
cell l ine HaCaT (35). Additionally, IL-4 and IL-13 are potent inhibitors of IL-1� 
induced IL-8 secretion by human intestinal epithelial cel ls (36). The mechanisms 
underlying the decreased IL-8 release under influence of IL-4 and IL-13 are as 
yet unknown, but they can be various in nature since both cytokines can signal 
through multiple pathways. 
In summary, we have described a mast cel l  model in which overnight (18 h) 
culturing of HMC-1 cells in the presence of IL-4/IL-13 and AMP/NECA results in 
enhanced h istamine release, which is accompanied by decreased A2A receptor 
expression and A2A/A28 receptor ratio. When translating this to the human 
situation, this mast cell model may mimic enhanced adenosine responsiveness 
that is present in asthma, suggesting a role for decreased A2AR expression. 
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Abstract 
Background: Adenosine is a signalling nucleoside that has been proposed to 
contribute to the pathogenesis of asthma. Adenosine is produced in inflammatory 
environments and acts via adenosine receptors (A1R, A2AR, A28R, and A3R) 
expressed by a wide variety of cells, resulting in pro- and anti-inflammatory 
effects. 
Objective: To compare adenosine receptor (AR) expression in asthma patients 
and healthy subjects, and to assess the effect of allergen challenge on AR 
expression of inflammatory cells and on cytokines in peripheral blood and sputum 
in asthma. 
Methods: Asthma patients underwent an allergen challenge, and blood and 
induced sputum samples were taken before and 24 h after allergen challenge 
to study inflammatory cells numbers, AR expression and cytokine production. 
Blood and sputum were investigated at one time point in healthy subjects. AR 
expression was measured by flow cytometry (blood) or on cytospins using 
immunocytochemistry (sputum). Cytokines (luminex, ELISA) and adenosine 
(HPLC) were measured in sputum supernatant. 
Results: The percentage of A28R expressing neutrophils in sputum was lower in 
asthma patients than in healthy subjects (p=0.016). Allergen challenge decreased 
A1R and A2AR expression on neutrophils and A1R expression on T cells in peripheral 
blood (all p<0.05). Allergen challenge increased IL-8 levels and eosinophils 
numbers (p<0.05), whereas it decreased thymic stromal lymphopoietin (TSLP) 
levels and the percentage of A1 R expressing macrophages in induced sputum 
(p<0.05). 
Conclusions: Allergen challenge has a down-regulatory effect on adenosine 
receptor expression in asthma, suggesting a ·  contribution of adenosine-related 
effector mechanisms in the pathophysiology. 
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Introduction 
Asthma is a chronic inflammatory disease of the airways characterized by episodes 
of wheezing, breathlessness, cough, and chest tightness (1). Several studies have 
shown a link between adenosine and the pathophysiology of asthma. Adenosine 
levels are elevated in bronchoalveolar fluid and exhaled breath condensate 
of asthma patients (2). In addition, adenosine 5'-monophosphate is able to 
induce bronchoconstriction in asthma patients, and this stimulus for bronchial 
hyperresponsiveness (BHR) has been shown to be superior to methacholine in 
demonstrating the presence of bronchial inflammation (3). 
Adenosine is a purine nucleoside that is released during tissue hypoxia and 
inflammation. Adenosine exerts its effects by activation of four different G protein 
coupled receptors, A1 (Gi coupled), A2A (Gs coupled), A28 (Gs and G 11 coupled)  and 
A3 (Gs and Gq11 coupled) .  Activation of the adenosine receptors (ARs) on different 
cell types can have different functions, and each receptor can be implicated either 
beneficially and/or detrimentally in the development or persistence of inflammation 
(4) . In short, both A2 receptors act mainly anti-inflammatory, whereas A1R and 
A3R act pro-inflammatory upon activation. 
There are no studies available in the literature investigating AR expression on 
inflammatory cells in asthma, or after allergen challenge. However, the effect of 
the adenosine A2A agonist GW328267X on the early and late airway response was 
investigated in two studies, one in asthma patients (5) and one in allergic rhinitis 
patients (6). In asthmatics, treatment with the inhaled adenosine A2A agonist 
GW328267X did not protect against the late asthmatic response, expressed as 
the fall in FEV1 5-8 h after allergen challenge, or the accompanying increase in 
airway inflammation, whereas the same drug had limited effects on the early­
and late response after nasal allergen challenge and clinical symptoms in allergic 
rhinitis patients, but showed a reduction in nasal tryptase levels. 
I 
In this study, the aim was to compare asthma patients and healthy individuals with 
respect to AR expression on inflammatory cells in blood and sputum. Furthermore 
we investigated the effect of allergen challenge on inflammatory cells, cytokine 
production and AR expression in blood and sputum cells of asthma patients. 
Knowledge on AR expression in stable disease and after allergen exposure is 




Subjects were recruited from the pulmonary outpatient clinic of the University 
Medical Center Groningen (UMCG) and the University Medical Center (UMC) 
Utrecht and by advertisements in local newspapers. We included 8 asthma 
patients and 10 asymptomatic healthy subjects. In addition, we used sputum 
material of 9 asthma patients derived from a previous study (5) .  For both studies 
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participants were included according to the following criteria: Asthma: forced . 
expiratory volume in 1 s (FEV1) � 70% predicted, provocative concentration of 
methacholine or histamine inducing a 20% fall in FEV1 (PC20) � 8 mg/ml, and 
at least one positive skin prick test for house dust mite, timothee grass, or cat 
dander. Healthy: FEV1 > 90% predicted during screening, PC20 methacholine > 8 
mg/ml, and negative skin prick test for inhalation allergens. All participants met 
the following criteria: age between 18-55 years, no current smoking, no use of 
inhaled corticosteroids in the previous 4 weeks, no use of oral corticosteroids in 
the previous 6 months, and no use of long-acting beta agonists in the previous 
2 weeks. Asthma patients were allowed to use a short-acting beta agonist if 
necessary. 
The local medical ethics committees (UMCG and UMC Utrecht) approved the 
study protocols and all subjects gave their written informed consent. 
design 
For asthma subjects, the study consisted of three visits to the outpatient clinic. 
During the first visit sputum was induced, at the second visit (3-4  days later) a 
blood sample was obtained and an allergen challenge was performed, and during 
the third and final visit (24 hours after start of the allergen inhalation) peripheral 
blood was withdrawn and sputum was induced. Patients were asked not to use 
short-acting beta agonists and caffeine containing drinks or food during and 8 
hours before allergen challenge. For healthy control subjects the study implied one 
visit to the outpatient clinic to obtain blood and to perform a sputum induction. 
Histamine, methacholine, and allergen challenge 
We applied the standardized guidelines for histamine, methacholine, and allergen 
challenge, employing the 2-min tidal breathing method (3). For the allergen 
challenge either house dust mite, cat, or timothee grass allergen (ALK Abell6, 
Hrzwsholm, Danmark) was used depending on the individual sensitivity of the 
subject as determined by skin prick tests at screening (5). 
Blood processing and FACS staining 
To isolate the leukocytes from peripheral blood, heparin blood was diluted 1:2 with 
phosphate buffered saline (PBS, pH 7.4) and centrifuged for 20 minutes at 1400g at 
room temperature. The buffycoat was withdrawn from the tube and erythrocytes 
were lysed using 10 ml of a lysingbuffer (150mM NH4CI, 10mM KHCO3, 0. lmM 
NA2EDTA * 2 Hp). Isolated leukocytes were stained for 1) co3mc (T cells), 2) 
CD2omc (B cells), and 3) CD14PercP (monocytes), CD11bPE and CD15mc (eosinophils 
and neutrophils), all from BD biosciences (Becton Dickinson, Franklin Lakes, USA). 
In the same samples, cells were also stained for the expression of three different 
adenosine receptors, A1, A2A' and A28 (Alpha Diagnostic International, San Antonio, 
TX, USA), secondary antibody used was allophycocyanin (APC) conjugated goat 
anti-rabbit IgG (Molecular Probes Europe BV, Leiden, The Netherlands). Cells 
were resuspended in FACS lysing solution (Becton Dickinson) and analyzed 
(4 x 104 events) using a FACS Calibur (Becton Dickinson). Raw data analysis was 
performed with FlowJo (TreeStar, San Carlos, CA). Cells were gated as followed: 
T cells CD3+, B cells CD20+, monocytes CD14+, eosinophils CD1410w, CD11bhi9h, 
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CD1610w, neutrophils CD1410w, CD11bhigh , and CD16high. In this specified populations 
the MFI (mean fluorescence intensity) of APC was calculated for AR expression. 
The antibody directed against A3R was not available at the start of the study, 
therefore, A3R was not included in the above analysis. 
Sputum induction, processing and AR immunostaining 
Sputum was induced by inhalation of hypertonic saline aerosols and processed 
as described previously (7). Sputum cytospin slides were stained with May­
GrUnwald-Giemsa for differential cell counts. Sputum samples containing >80% 
of squamous cells were excluded from analysis. For immunostaining, cytospin 
slides were dried and fixed in acetone for 10 minutes, dried for 30 minutes and 
washed with PBS. Hydrogen peroxide in methanol was used for blocking of 
endogenous peroxidase. The following polyclonal antibodies were used: rabbit 
anti-rat adenosine Ai receptor, rabbit anti-canine adenosine A2A receptor, rabbit 
anti-human adenosine A28 receptor (all from Alpha Diagnostic International), and 
rabbit anti-human adenosine A3 receptor (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA). Antibodies directed against adenosine Ai and A2A receptors were 
raised against rat and canine, respectively, but cross-reacted with human. Rat 
and canine ARs show 100% and 80% homology with human ARs respectively. 
Secondary antibody used was goat anti-rabbit biotin conjugated (SBA, Birmingham, 
AL, USA) and tertiary antibody StreptABComplex peroxidase conjugated (DAKO, 
Glostrup, Denmark). As chromogen, 3-amino-9-ethyl-carbazol (AEC) substrate 
was used; tissue was counterstained with Mayers' Haematoxyllin. Three hundred 
neutrophilic granulocytes and 300 macrophages were counted in each cytospin, 
and scored as negative or positive; the percentage of cells expressing adenosine 
receptors was calculated. Due to the small numbers of lymphocytes present in 
sputum we could not reliably quantify adenosine receptor expression on this cell 
type. Since only few patients showed more than 10% of eosinophils in sputum, 
we 'did not quantify adenosine receptor expression on eosinophils. 
Measurement of adenosine in sputum supernatant using HPLC-MS 
Adenosine was measured using a Waters 2690 Alliance Separation Module HPLC 
system (Waters, Milford, Massachusetts, U.S.A.) coupled on-line to a Finnigan TSQ 
Quantum Triple Quadruple Mass Spectrometer (Finnigan Thermo Fisher Scientific, 
Waltham, MA, U.S.A.). Chromatographic separation was performed with a C18, 3 
µm, Atlantis column (Waters) 2. 1 mm I.D. x 100 mm length using a gradient of 
mobile phase A (ammonium acetate 20 mM pH 7.0 in water) and B (ammonium 
acetate 20 mM, pH 7.0, in acetonitrile) at 0.2 ml/min flow rate. Before measurement 
samples were pre-treated as follows: 100 µ I  of sputum supernatant were acidified 
with 20 µI of HCI 120 mM, then 200 µI of chloroform was added to precipitate 
proteins and eliminate lipids. After vortexing and subsequent centrifugation, 80 
µI of the aqueous supernatant was transferred to a glass injection vial and 5 µI of 
this solution was injected into the HPLC- MS system. MS detection was performed 
using ESI ionization in positive ion mode. To increase the sensitivity multiple 
reaction monitoring mode (MRM) was used. Adenosine was quantified using the 
transition m/z 260 > m/z 136 corresponding to the loss of the ribofuranose ring. 
Samples were measured in a randomized way, twice independently at two 
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Table 1. Patient characteristics 
Age FEV1 FEV1 PC20 PC20 Allergen LAR 
(yrs) (I) (0/opred) Methacholine Histamine 
(mg/ml) (mg/ml) 
Asthma 
1 27 4.32 88 0.84 HDM 
2 24 4.27 92 2.50 HDM + 
3 46 2.41 85 0.60 HDM + 
4 52 2.56 89 0.16 HDM + 
5 53 2 .28 80 0.19 HDM 
6 41 3 .60 124 0.68 Cat 
7 41 4.69 113 6.13 Grass + 
8 47 3 .27 116 1 .06 Cat 
9# 54 3.48 104 4.84 Grass + 
10# 19 3.95 105 1.84 HDM + 
11# 21 3.99 81 0.57 HDM + 
12# 27 5.14 100 1 .67 HDM + 
13# 18 4.12 115 1.81 HDM + 
14# 21 3 .50 75 2.67 Grass + 
15# 20 4.82 98 0.29 Grass + 
16# 20 4.85 94 4.43 Grass + 
17# 18 4.10 94 0.94 HDM + 
Healthy 
1 25 4.86 129 
2 37 3.98 122 
31 31 5.05 114 
4 25 4.05 111 
51 44 3.80 105 
6 21 3 .89 97 
7 29 4.50 124 
8 33 3 .56 114 
9 29 4.02 118 
102 20 4.50 99 
#AR expression was only determined in sputum cells; in sputum supernatant adenosine was measured only. 1no sputum 
cytospins of sufficient quality. 2no sputum induced. FEV1, forced expiratory volume in 1 s; PC201 provocative concentration 
of methacholine or histamine inducing a 20% fall in FEV1; HDM, house dust mite; LAR, late asthmatic response; -, PC20 
methacholine > 8 mg/ml. 
different days; results were in good agreement within a maximum of 10% 
variation. The calibration line consisted of 8 points in the range of 5 to 1000 ng/ 
ml adenosine in a mixture of PBS and water (pretreated in the same way as the 
study samples). 
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Measurement of cytokines in sputum supernatant 
In sputum supernatant levels (sensitivity level) of IL-4 (5 pg/ml), IL -5 (3 pg/ml), IL-
8 (3 pg/ml), IL-13 (10 pg/ml), IL-17 (10 pg/ml), MCP-1 (10 pg/ml), RANTES (15 pg/ 
ml), eotaxin (5 pg/ml), IFN-y (5 pg/ml) and TNF (10 pg/ml) were measured using 
Human Custom Ten-plex Antibody Bead Kits from Biosource International, Inc. 
(Camarillo, California, USA) in accordance with the manufacturers' instructions. 
Standard solutions were diluted with sputolysin reagent (Calbiochem®, 
Darmstadt, Germany) to mimic the effect it might have had on sputum content 
during processing. 
Thymic stromal lymphopoietin (TSLP) levels in induced sputum supernatant were 
measured using the TSLP ELISA kit from R&D Systems, Inc. (Minneapolis, USA) 
according to the manufacturers' instructions. Standard solutions were diluted 
with sputolysin reagent (Calbiochem®) to copy the effect it might have had on 
sputum content during processing. 
Statistical analysis 
Statistic analyses were performed using a Wilcoxon signed rank test, a non­
parametric paired test to test for differences within the groups and a non­
parametric Mann-Whitney U test to test for differences between both groups at 
baseline. A value of p < 0.05 was considered significant. Correlations between 
parameters were investigated using Pearsons Rho test. 
Results 
Patient characteristics are shown in table 1. Patients with asthma exhibited 
bronchial hyperresponsiveness to methacholine or histamine whereas healthy 
control subjects did not. In addition, asthma patients had a lower FEV1 (% 
predicted) compared to healthy controls (p = 0.008), as well as higher percentages 
of blood eosinophils (p = 0.002), numbers of sputum leukocytes (p = 0.033, Table 
2), and percentages of sputum eosinophils (p = 0.001). Allergen challenge did 
not affect the absolute number of sputum cells, but increased the percentage of 
sputum eosinophils (p = 0.018). Allergen challenge had no effect on peripheral 
blood cell numbers or cell differentials. 
Adenosine receptor expression on peripheral blood cells 
In peripheral blood, all five cell types studied (eosinophils, T cells, neutrophils, 
monocytes, and B cells) expressed A1R, A2AR, and A28R. Asthma patients tended 
to have a higher expression of A1R (p = 0.06) on T cells and A2AR (p=0.06) on 
monocytes than healthy controls (Figure 1). Allergen challenge decreased A1 R 
expression on T cells (p = 0.04) and A1 R and A2AR expression on neutrophils (p 
= 0.012). There were no significant differences in AR expression on B cells (data 
not shown) and eosinophils (Figure 1). 
Adenosine receptor expression on sputum cells 
In sputum, both neutrophils and macrophages expressed all four described 
adenosine receptors. Investigating the percentage of cells expressing adenosine 
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Figure 1. Adenosine receptor expression on eosinophils (A), T cells (B), neutrophils (C), and 
monocytes (D) in peripheral blood of healthy and asthma subjects. Before: before start of 
allergen challenge; after: 24 h after allergen challenge (asthma patients). MFI: mean fluorescence 
intensity. Significant differences are indicated in the graphs. 
than healthy subjects (p = 0.016, Figure 2A). There was a positive correlation 
between the absolute numbers of neutrophi ls in sputum and numbers of 
neutrophils expressing A28R (Rho 0.888, p = 0.000, plot not shown). 
Allergen challenge decreased the percentage A1R expressing macrophages in 
asthma patients (p = 0.012, Figure 2B). 
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Table 2. Peripheral blood and sputum cell counts 
Healthy Asthma 
before (allergen challenge) after 
Peripheral blood N=l0 N=8 N=8 
Cell concentration (xl06/ml) 5.4 (4.3-7.3) 4.8 (4.5-5.9) 5.0 (4.3-7.7) 
Eosinophils (%) 1 .7 (0.5-3.4) 5.9 (1.7-10.1)* 6.3 (2.3-7.9) 
Lymphocytes (%) 38.1 (27.7-49.3) 29.8 (20.6-43.1) 29.3 (16.7-43.8) 
Neutrophils (%) 50.5 (5.4-62.8) 56.3 (42.7-63.9) 56.2 (41 .5-68.2) 
Monocytes (%) 6.8 (0.3-12.1) 8.4 (5.4-9.9) 7.9 (5.6-9.9) 
Sputum N=7 N=17 N=17 
Total cell count (xl06) 1.8 (0.0-4.0) 6.4 (0.0-19.6)* 4.5 (0.5-17.9) 
Eosinophils (%) 0.0 (0.0-1. 7) 5.4 (0.0-36.8)* 31.1 (0.0-58.0)' 
Lymphocytes (%) 2.0 (0.3-3.0) 2.1 (0.0-8.3) 1.2 (0.0-10.5) 
Neutrophils (%) 32.7 (4.5-70.5) 44.3 (5.0-74.2) 28.8 (0.0-76.3) 
Macrophages (%) 63.0 (24.7-93.5) 39.4 (13.2-90.0) 32.3 (15.2-95.0) 
Data presented as median (range). * p<0.05 compared to healthy subjects. • p<0.05 compared to before allergen challenge 
Inflammatory mediators in sputum supernatant 
In sputum supernatant, levels of adenosine and various cytokines were measured. 
IL-8 levels increased in sputum of asthma patients fol lowing allergen challenge 
(p = 0.028), whereas levels of TSLP decreased (p = 0.036, Figure 3) . Before 
al lergen chal lenge, there was a significant correlation between IL-8 levels and 
total number of neutrophils in sputum (Rho 0.626, p = 0.017, total group), a 
correlation that was no longer significant following allergen challenge. Adenosine 
and cytokine levels d id not d iffer comparing hea lthy and asthma subjects, nor d id 
al lergen challenge a lter these levels. Levels of IL-5, IL-13, eotaxin, and TNF were 
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Figure 2. Adenosine receptor expression on neutrophils (A) and macrophages (B) in sputum 
of healthy and asthmatic subjects. Before: 3-4 days before al lergen challenge; after: 24 h after 
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Figure 3. Levels of IL-4, IFN-y, TSLP, IL-8, RANTES, MCP-1, IL-17, and adenosine in sputum 
supernatant of healthy and asthmatic subjects. Before: 3-4 days before al lergen challenge; after: 
24 h after allergen challenge (asthma patients). *: two samples contained > 12,000 pg/ml IL-8. 
Significant differences are indicated in the graphs. 
Discussion 
We investigated the role of adenosine and adenosine receptors in asthma by 
comparing asthma patients and healthy controls. In addition, we assessed 
whether al lergen-induced airway inflammation in asthma is associated with a 
change in AR expression on peripheral blood and induced sputum cells. Our 
results show that asthma patients had an increased number of eosinophils in 
peripheral blood and induced sputum, and that these numbers further increased 
after a l lergen challenge. These findings support previous studies by our group 
and others (8-21). However, AR expression on blood eosinophils in asthma did not 
differ from healthy controls nor d id it change upon a l lergen challenge, thus not 
explaining this increased eosinophil migration. 
The increase in eosinophil numbers was accompanied by higher levels of IL-8. 
Eosinophils can produce IL-8 and could be responsible for enhanced levels of IL-
8 upon al lergen challenge (22;23). However, eosinophils do not migrate by IL-8 
whereas neutrophils do. A trans-basement membrane migration study has shown 
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that IL-8 attracts eosinophils only when neutrophils are present and it could be 
that neutrophils migrated by IL-8 may have led eosinophils to accumulate in the 
airways of patients with asthma (24). Enhanced levels of IL-8 in induced sputum 
were also described earlier and support our correlation with neutrophils and IL-8 
in asthma before allergen challenge (16). 
This study showed that the AR expression on other peripheral blood cell 
types was not significantly different in asthma and healthy subjects. However, 
after allergen challenge, A1R expression was down regulated on T cells and 
neutrophils, as was A2AR expression on neutrophils. Data of A1R on T cells are 
scarce. Takahashi and co-workers described the anti-inflammatory effects of an 
A2AR agonist (CGS-21680) on cytokine production and lymphocyte proliferation 
(25). However, when co-incubated with an A1R agonist (N6-cyclopentyladenosine, 
CPA), the anti-inflammatory effects induced by CGS-21680 were reversed, 
resulting in increased cytokine production and lymphocyte proliferation. These 
results suggest a pro-inflammatory role for A1R on lymphocytes. In addition, 
the A1R is described to be Gi-protein coupled. Activation of the receptor inhibits 
adenylyl cyclase activation and subsequent cAMP production, which also points 
towards a pro-inflammatory role of A1 receptors. Our observed decreased A1 R 
expression on T cells following allergen challenge could indicate a compensatory 
mechanism in peripheral blood of asthma patients in an effort to protect against 
ongoing inflammation. This could also be the role of the observed decrease in A1 R 
expression on neutrophils after allergen challenge, since activation of the A1 R on 
neutrophils induces chemotaxis and increases the adherence to endothelial cells 
(26-28). Interestingly, A2AR expression on neutrophils was also down regulated 
after allergen challenge. This is an intriguing observation since activation of both 
receptors has opposite effects. Activation of A2AR reduces neutrophil adherence 
to endothelium (26), uncouples chemo attractant receptors from their stimulus­
transduction-proteins (29), and inhibits generation of toxic oxygen metabolites 
and degranulation (30). This indicates that reduced expression of this receptor 
could induce neutrophil activation, thereby permitting neutrophils to release 
greater quantities of free oxygen radicals with consequently increased oxidative 
damage (27;31). Together these data suggest that a disturbance of the delicate 
balance between A1R and A2AR may ultimately results in a positive or negative 
effect on neutrophilic inflammation. 
We found expression of all four adenosine receptors on sputum neutrophils and 
macrophages in asthma patients and healthy control subjects. The percentage 
of neutrophils expressing A28R was lower in asthmatics and allergen challenge 
decreased the percentage of macrophages expressing A1 R. Adenosine A28 
receptors have been described to inhibit trans-endothelial migration of neutrophils 
upon activation (32). This is of interest since the absolute number of neutrophils 
was positively correlated to the absolute number of neutrophils expressing A28R. 
Similar to A2AR expression, loss of A28R expression on neutrophils can induce 
increased production of free oxygen radicals with consequent oxidative damage in 
the lung (31). For scleroderma, a connective tissue disease of unknown aetiology, 
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a reduced expression and activity of A28R on blood neutrophils compared to 
healthy control subjects has been reported as well (31). 
We detected a down regulatory effect of allergen challenge on the percentage of 
sputum macrophages that express Ai R. Activation of Ai R on macrophages has been 
described to inhibit LPS-induced TNF and IL-10 production (33). Also, occupancy 
of Ai R on macrophages results in a very rapid and marked enhancement of FcyR 
function, resulting in enhanced FcyR-mediated phagocytosis (28). In multiple 
sclerosis (MS), reduced Ai R protein and RNA levels were detected in cells of 
the monocyte/macrophage lineage. According to the authors, this decreased Ai R 
expression by macrophages may contribute to the progression of MS by decreasing 
the ability of adenosine to regulate the inflammatory response in the brain (34). 
When translating this to our allergen challenge setting in asthma patients, we 
found a decreased expression of Ai R on macrophages following allergen challenge 
which also could prevent adenosine to regulate the inflammatory response in the 
airways/sputum, and hereby explaining worsening of inflammation and symptoms 
following an allergen induced exacerbation. 
A number of sputum cytokines were measured that are related to the pathogenesis 
of asthma. Asthma patients and healthy controls had similar levels of cytokines 
in sputum, but the levels of TSLP decreased after allergen challenge, whereas 
IL-8 levels increased. TSLP is a cytokine produced by airway epithelium, smooth 
muscle cells and mast cells and is capable of directing dendritic cells towards a 
Th2 response, thereby providing a link between epithelial cell activation/injury 
and an allergic type of inflammation. In this study, levels of TSLP in sputum were 
not different when comparing asthma patients with healthy subjects. This is the 
first study in which levels of TSLP were measured in sputum. TSLP expressing 
cells, measured by immunohistochemistry and mRNA, were described to be 
increased in bronchial biopsies from asthma patients (35). To our surprise, allergen 
challenge decreased TSLP levels in sputum of asthma patients. Epithelial cells 
are the main producers of TSLP. We speculate that allergen challenge may have 
altered TSLP production temporarily because of production of other cytokines 
or growth factors involved in repair. Further studies have to elucidate the role of 
TSLP in asthma severity or progression. 
In summary, this is the first study that reports on AR expression on different cell 
types in peripheral blood and sputum of healthy controls and asthma patients, 
and the change with allergen challenge in asthma. Asthma patients had lower 
A28R expression on sputum neutrophils than healthy controls. Furthermore, 
allergen challenge decreased Ai R expression on blood neutrophils and sputum 
macrophages, and A2AR on blood neutrophils. This may contribute to the enhanced 
inflammation in asthma after allergen inhalation. This study contributes to a better 
insight in the role of adenosine and its receptor in asthma. Further studies should 
include experiments on intracellular pathways of adenosine receptor stimulation 
in order to get more insight in the downstream effects as well. 
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Background.· Airway hyperresponsiveness (AHR) to adenosine 5'-monophosphate 
(AMP) is significantly increased in smokers with COPD and healthy smokers 
compared to non-smokers. AMP-induced AHR is thought to be induced mainly 
through activation of adenosine A28 receptors (A28Rs) that are expressed on 
airway mast cells. Therefore, we set out to investigate the effects of cigarette 
smoke extract (CSE) on adenosine responsiveness of the human mast cell line 1 
(HMC-1). 
Methods: HMC-1 cells were incubated either with 10% CSE (2 cigarettes/25ml 
= 100%) alone, or with CSE for 30 minutes followed by AMP in combination 
with 5'-N-ethylcarboxamidoadenosine (NECA, non-specific adenosine receptor 
agonist). To investigate involvement of A2Rs cells were additionally pre-incubated 
with a specific A2AR antagonist (ZM 241385) or a non-specific AR antagonist 
(theophylline) together with CSE, before incubation with AMP/NECA. Adenosine 
responsiveness of the HMC-1 cells was determined by measurement of A2A and 
A28 receptor expression and mast cell degranulation. To investigate A2R-related 
intracellular pathways, cAMP and intracellular calcium were measured. 
Results: Incubation with CSE alone increased A2AR and A28R expression 
(P<0.05) and mast cell degranulation, accompanied by increased intracellular 
calcium concentrations. Theophylline protected against CSE-induced mast cell 
degranulation, accompanied by increased cAMP and decreased intracellular 
calcium levels (p<0.05 ). Interestingly, theophylline also protected against CSE/ 
AMP/NECA-induced mast cell degranulation. ZM 241385 enhanced degranulation 
only in the presence of AMP/NECA and not with CSE alone. 
Conclusion: CSE-induced effects on mast cells may act via the A28 receptor, 
either directly by binding of CSE, or via indirectroutes that enhance endogenous 
adenosine which can bind to the adenosine A28 receptor. Our findings suggest a 
possible role for specific A28R antagonists in the treatment of COPD. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a major and still growing 
health problem with increasing mortality worldwide. It is characterized by poorly 
reversible airflow limitation that is usually progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases, 
particularly cigarette smoke (1). Mast cells normally reside close to epithelia, 
blood vessels, nerves, smooth muscle cells, and mucus-producing glands 
(2), and are described to be involved in the development of smoking-related 
peripheral lung injury (3). Mast cell activation may also contribute to airway 
hyperresponsiveness (AHR), a feature present in about 70% of the patients with 
COPD (4). AHR to adenosine 5'-monophosphate (AMP) is present in smokers with 
COPD, but also in healthy smokers (5). Moreover, smokers have higher levels 
of adenosine in their airway lining fluid (6) and smoking cessation results in 
reduction of AMP hyperresponsiveness (7). The potent and selective histamine 
receptor-antagonists terfenadine and astemizole have been shown to potently 
inhibit the bronchoconstrictor response to adenosine both in asthma and COPD, 
suggesting that histamine is the predominant mast cell mediator involved in the 
airway response to this nucleotide (8,9). 
Inhaled AMP is dephosphorylated by 5'-ectonucleotidase to form adenosine, 
which acts via adenosine receptors, of which four different G-protein-coupled 
receptors have been described, adenosine A1, A2A' A28 and A3 receptors. The 
main mechanism of adenosine-induced bronchoconstriction appears to involve 
the release of inflammatory mediators from mast cells via activation of the 
A28 receptor. However, adenosine can also act on the other receptors. Cells 
of the leukemic human mast cell line 1 (HMC-1) express functional A28 and A2A 
receptors, which are both coupled to adenylyl cyclase via Gs -protein. Activation 
of this pathway results in accumulation of cAMP and stimulation of protein kinase 
A. Adenosine A28 receptors are also coupled to phospholipase C� via a GTP­
binding protein of the G family. Activation of this pathway results in increases 
in diacylglycerol (DAG) �nd inositol triphosphate (IP3).  DAG stimulates protein 
kinase C and IP3 activates mobilization of intracellular calcium (10). The A2A and 
A28 receptors are distinguished by their respectively high and low affinity for 
adenosine (11). Activation of A2A receptor results in suppression of histamine and 
tryptase release from human mast cells (12). Strong evidence for the critical role 
of A2A receptors in the regulation of inflammation in vivo is obtained from a study 
using A2AR deficient mice which have enhanced tissue inflammation and damage 
in their lungs, suggesting a negative regulatory role for the A2A receptor subtype 
(13). Activation of the A28 receptor on the other hand up regulates inflammatory 
cytokine production (IL-3, IL-4, IL-8, IL-13) in mast cells and promotes IgE synthesis 
by B lymphocytes (14,15). In vitro studies with selective A28 receptor antagonists 
have shown to potently suppress the activation and degranulation of human mast 
cells induced by adenosine (16). 
Little is known about the expression and regulation of adenosine receptors after 
cigarette smoke (CS) exposure, nor about the mediator release by mast cells 
after exposure to CS. Since AMP-induced AHR is described to act by binding of 
adenosine to the adenosine A28 receptor on mast cells, we were interested to 
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learn more about CS in relation to A2R expression, intracellular pathways, and . 
mediator release of mast cells. Therefore we set out to study this in a model by 
stimulating HMC-1 cells with cigarette smoke extract (CSE). 
Material and Methods 
Cell culture 
Cells of the human mast cell line 1 (HMC-1, a generous gift from dr. J.H. Butterfield, 
Mayo Clinic, Rochester MN) were maintained in suspension culture at a density 
between 0.8 and 2.0 x 106 cells/ml by culturing in Iscove's Modified Dulbecco's 
Medium (IMDM, Gibco®, Invitrogen, Paisley, United Kingdom) supplemented with 
10% (v/v) heat inactivated fetal calf serum (FBS, Gibco®), 1.23 mM L-glutamine 
(BioWhittaker, Verviers, Belgium), 100 U/ml penicillin (BioWhittaker), 100 µg/ml 
streptomycin (BioWhittaker), 5 µg/ml apo-transferrin (Sigma, St. Louis, USA), and 
50 µM �-mercaptoethanol (Gibco®). Cells were kept under humidified atmosphere 
of air/CO2 (19:1) at 37 
°c. 
Preparation of Cigarette Smoke Extract {CSE) 
Cigarette smoke extract (CSE) was freshly prepared for each experiment as 
described by the method of Van der Toorn et al. (17). In short, smoke from two 
standardized 2R4F research cigarettes without filters (Tobacco Health Research 
institute, University of Kentucky), was bubbled into 25 ml of serum-free IMDM 
(100%). Each cigarette was smoked in 5 min with a 17-mm butt remaining. The 
resulting extract was used within 30 min after preparation. 
Viability measurement 
To study the effect of CSE on HMC-1 viability, cells (1 x 106 cells/ml, n=8) were 
incubated with increasing concentrations of CSE (0, 2.5, 5, 10, and 20%) for 30 
min. or 2 hours. 10 µI cell suspension was mixed with 10 µI trypan blue solution 
(GIBCO™) and cells stained blue were considered non-viable cells, whereas the 
cells that excluded the stain were considered viable. 
Stimulation of HMC-1 cells with CSE 
HMC-1 cells, cells (1 x 106 cells/ml, n=8) were incubated with CSE (0, 2.5, 5, 
10, and 20%) for 2 hours, harvested and centrifuged at 500g for 5 minutes at 
4 °C. A2A and A28 receptor expression was determined by flow cytometry and 
cells were used for preparation of cytospins for tryptase staining. In addition, 
supernatants were collected, stored at -80°C, and used to determine histamine 
levels by ELISA. 
Stimulation of HMC-1 cells with CSE and theophylline or ZM 241385 
HMC-1 cells (1 x 106 cells/ml, n=6) were incubated with 1.5 mM theophylline (non­
selective adenosine receptor antagonist, Sigma-Aldrich Chemistry, Zwijndrecht, 
the Netherlands) or with 100 nM ZM241385 (selective A2AR antagonist, Tocris 
bioscience, Northpoint, United Kingdom) in combination with O or 10% CSE for 2 
hours. Incubation occurred under humidified atmosphere containing 5% CO2 at 
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37 °C . At the end of the incubation period, HMC-1 cells were harvested and used 
for flowcytometry and cytospin preparation. 
Stimulation of HMC-1 cells with CSE, AMP/NECA, theophylline and ZM 
241385 
HMC-1 cells (1 x 106 cells/ml, n=6) were pre-incubated with 1.5 mM theophylline 
or with 100 nM ZM 241385 in combination with O or 10% CSE for 30 minutes. 
After pre-incubation, HMC-1 cells were stimulated with 0.1 µM AMP and 1 µM 5'­
N-ethylcarboxamidoadenosine (NECA, non-selective adenosine receptor agonist) 
(both from Sigma-Aldrich Chemistry) during an additional incubation period of 
90 minutes. At the end of the incubation period with AMP and NECA, cells were 
harvested and treated as described before. 
Adenosine A2A and A28 receptor expression 
Expression of adenosine A2A and A28 receptors on the HMC-1 cells was analyzed 
using flow cytometry. HMC-1 cells (0.5  x 106 per sample) were incubated with 
the primary antibodies rabbit anti-human A28R and rabbit anti-canine A2AR (cross­
reactivity with human), both from Alpha Diagnostic International (San Antonio, 
USA), and thereafter with the secondary fluorescein isothiocyanate conjugated 
(FITC) goat anti-rabbit IgG (Becton Dickinson, Franklin Lakes, USA) . Cells were 
resuspended in FACS lysing solution (Becton Dickinson) and 40,000 events per 
sample were measured using a FACS Calibur (Becton Dickinson). Data generated 
by FACS Calibur was analyzed using FlowJo (TreeStar, San Carlos, United States). 
MFI (mean fluorescence intensity) of the positive FITC population was calculated. 
The gate to calculate the MF! of FITC positive cells was set in the FITC histogram 
of unstained cells. The gate was set at the point were less than 1% of the cells 
was FITC positive, and copied to all other samples. In the first experiment an 
isotype control was added (normal rabbit IgG), and its histogram was similar to 
unstained cells. 
Measurement of histamine by ELISA 
Histamine levels in supernatants were measured using ELISA (IBL, Hamburg, 
Germany) according to the manufacturers' instructions. 
Tryptase staining 
To determine degranulation, tryptase staining was performed on cytospins of 
stimulated cells. Cytospins were prepared using a cytocentrifuge (Cytospin 2, 
Shandon), 100 µI of cell suspension (0. 5  x 106 cells/ml) was spotted on a glass 
slide at 450 rpm for 6 minutes. Cells were fixed on the glass slides by incubation 
in acetone. Cytospins were incubated with the primary antibody mouse anti­
human mast cell tryptase antibody AAl (DAKO, Glostrup, Denmark) .  To localize 
the unconjugated primary antibody, cytospins were incubated with the secondary 
antibody rabbit anti-mouse biotin conjugated (RaMbio, DAKO), followed by the 
tertiary antibody streptavidin-alkaline phosphatase conjugated antibody (StrepAF, 
DAKO). The immunoreaction was visualized using Fast Red TR (Sigma) substrate. 
Cells were counterstained with Mayers' haematoxylin. In each cytospin, 300 cells 
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were scored positive or negative with a light microscope, to obtain a percentage 
of positive cells. 
Intracellular cyclic AMP {cAMP) measurement 
Cyclic AMP was measured using an EnzymeimmunoAssay (EIA) system from 
Biotrak (Amersham, United Kingdom). After incubation of the HMC-1 cells with 
the appropriate stimulation, 100 µI of cell suspension was centrifuged (500g, 
5 minutes) in a standard 96-wells microplate. The acquired pellet was treated 
according to the manufacturers' instruction. 
Intracellular calcium measurement 
HMC-1 cells (1 x 106 cells/ml, n=6) were incubated for 30 minutes with the Fluo-
3/AM ester (50 µg/ml, Invitrogen, Paisley, United Kingdom), prior to incubation/ 
stimulation with CSE, theophylline or ZM241385, and AMP/NECA (according to the 
protocol like mentioned before) under humidified atmosphere containing 5% CO2 
at 37 °C. After the incubation period with AMP and NECA, cells were harvested 
and centrifugated for 5 minutes at 500g (4 °C). Cell pellets were resuspended in 
250 µ I  FACS lysing solution and 20,000 events per sample were measured with a 
FACS Calibur. Data generated by the FACS Calibur was analyzed using FlowJo. 
Statistical analysis 
Statistics were performed using the nonparametric Kruskal-Wallis test, and if 
significant with a Mann-Whitney U-test for post testing. A value of p < 0.05 was 
considered significant. 
Results 
Effects of CSE on viability of HMC-1 cells 
· CSE has been shown to switch on apoptotic pathway(s) as a result of oxidative 
stress (18). Therefore, viability of HMC-1 cells was measured for their response to 
the effects of CSE. As shown in figure 1, CSE exposure at the doses used (2.5-
20%) slightly decreased viability of HMC-1 cells with increasing concentrations 
of CSE, with a maximum decrease of 13% when stimulated with 20% CSE for 
120 minutes. There was no significant difference with time of dosing, i.e. similar 
effects occurred after 30 minutes and 120 minutes. Viability decreased with only 
7% when cells were stimulated with 10 % CSE for 30 minutes and we decided to 
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Figure 1. Viability of HMC-1 cells after 
incubation with different concentrations 
cigarette smoke extract (CSE) for 30 (dark 
bars) or 120 minutes (light bars). Data 
presented as mean with SEM. * p < 0.05 
vs. 0% CSE. 
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Figure 2. Adenosine A2A (A) and A28 (B) receptor expression, tryptase expression (C), and 
histamine release (D) by HMC-1 cells following 2 hours stimulation with increasing concentrations 
of cigarette smoke extract (CSE). Data presented as mean with SEM. * p < 0.05 vs. 0% CSE, # 
p < 0.05 vs. 2.5% CSE. 
CSE up regulates A2 receptor expression and mediator release on HMC-
1 cells 
As shown in figure 2, a dose dependent effect of CSE was seen in up regulation 
of the adenosine A2A receptors (Figure 2A) compared to non-stimulated control 
cells. The highest receptor expression was detected upon stimulation with 20% 
CSE (p=0.038). CSE additionally up regulated A28 receptor expression (Figure 2B, 
p< 0.05) without significant changes with increasing CSE doses. 
To investigate degranulation of HMC-1 cells upon CSE stimulation, the number of 
cells expressing tryptase was counted on cytospins. We reasoned that a decrease 
of the number of tryptase-expressing cells was a good measure for degranulation. 
In addition, histamine release was determined in supernatants of these cells. 
Figure 2C shows that increasing concentrations of CSE resulted in a decrease 
in percentage of tryptase positive cells, which was accompanied by a significant 
increase in histamine (Figure 2D). 
CSE incubation in combination with theophylline and ZM 241385 
To investigate the specific role of the A2A and A28 receptors in the effects of CSE on 
HMC-1 degranulation, we added the non-selective adenosine receptor antagonist 
theophylline and the specific adenosine A2A receptor antagonist ZM 241385. Figure 
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Figure 3. Adenosine A2A (A) and A28 (B) 
receptor expression and tryptase expression 
(C) by HMC-1 cells following 2 hours 
stimulation with 10% cigarette smoke extract 
(CSE) in combination with the non-selective 
adenosine receptor antagonist theophylline 
or the specific A2AR antagonist ZM 241385. 
Data presented as mean with SEM. * p < 
0.05 vs. 0% CSE, # p < 0.05 vs. 10% CSE. 
significantly after stimulation with 10% CSE compared to non-stimulated cells, as 
shown earlier. Both antagonists protected against CSE-induced up regulation of 
the A2AR, whereas no effect was seen on CSE-induced up regulation of the A26R. 
Interestingly, but against our expectation, both antagonists protected against 
CSE-induced mast cell degranulation as measured by tryptase expression (Figure 
3C, p<0.05). 
Theophylline alone did not alter adenosine receptor expression, whereas ZM 
241385 slightly decreased (p<0.05) expression of A28R compared to control (data 
not shown). 
Effect of CSE, theophylline and ZM 241385 on intracellular calcium and 
cAMP 
To obtain insight in the effect of CSE on intracellular pathways that are involved 
in A2R-induced degranulation of the mast cell, cAMP (which is increased upon Gs -
coupled A2A Rand A28Ractivation) and intracellular calcium concentrations (increased 
upon G
q 
-coupled A28R activation (19)) were investigated after stimulation with CSE 
in combination with both antagonists. CSE itself did not affect cAMP concentrations 
(Figure 4A), but increased intracellular calcium when compared to unstimulated cells. 
Theophylline increased the level of CSE-induced cAMP significantly (p<0.05) and 
decreased CSE-induced intracellular calcium (p<0.05). ZM 241385 also increased 
the level of CSE-induced cAMP, but to a lower extent, and increased CSE-induced 
intracellular calcium (p<0.05). Incubation with both antagonists alone had no 
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Figure 4. cAMP (A) and intracellular calcium (B) measured in HMC-1 cells following 2 hours 
stimulation with 10% cigarette smoke extract (CSE) in combination with the non-selective adenosine 
receptor antagonist theophylline or the specific A2AR antagonist ZM 241385. Data presented as 
mean with SEM. * p < 0.05 vs. 0% CSE, # p < 0.05 vs. 10% CSE. 
Effect of pre-incubation of CSE on AMP/NECA stimulated cells 
Since AMP inhalation induces airway obstruction likely due to A28 receptor 
stimulation on mast cells, AMP in combination with an adenosine receptor agonist 
(NECA, which has the highest affinity for the A28R) was added to our experiment. 
Figure SA and B show that expression of both the A2A and A28 receptor significantly 
increased after stimulation with CSE in combination with AMP/NECA. Stimulation 
with AMP/NECA alone (0% CSE) had no effect on A2R expression when compared 
to the non-stimulated control (data not shown). 
Figure SC shows that stimulation of cells with the combination of CSE and AMP/ 
NECA enhanced degranulation of mast cells as measured by tryptase release 
when compared to control (p<0.05), which was accompanied by increased levels 
of cAMP and intracellular calcium (Figure 5 D and E, p<0.05). Stimulation with AMP/ 
NECA alone resulted in increased histamine release accompanied by a decreased 
percentage of tryptase positive cells; furthermore cAMP levels increased, and no 
alteration in intracellular calcium was detected (data not shown). 
In addition, to investigate again the specific role of the A2A and A28 receptors in 
the effects of CSE/AMP/NECA on HMC-1 cells, both A2 receptor antagonists were 
added to the experiment. Theophylline did not change CSE/AMP/NECA-induced 
A2AR (Figure SA) and A28R (figure SB) expression, whereas ZM 241385 significantly 
decreased A2AR expression (p<0.01). With respect to degranulation, theophylline 
protected against CSE/AMP/NECA-induced tryptase release, whereas ZM 241385 
did not. The observed protective effect of theophylline was accompanied by 
decreased CSE/AMP/NECA-induced intracellular calcium levels (Figure SE, p<0.05), 
with no effect on CSE/AMP/NECA-induced cAMP (Figure SD). ZM 241385 had no 
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Figure 5. Adenosine A2A (A) and A28 (B) 
receptor expression, tryptase expression 
(C), cAMP (D) and intracellular calcium 
(E) by HMC-1 cells following 30 min. pre­
incubation with 10% cigarette smoke 
extract (CSE) in combination with the non­
selective adenosine receptor antagonist 
theophylline or the specific A2AR antagonist 
ZM 241385, with subsequent stimulation 
with AMP/NECA for 1.5 hour. Data 
presented as mean with SEM. * p < 0.05 
vs. 0% CSE, # p < 0.05 vs. 10% CSE, oo p 
< 0.05 vs. 10% CSE + AMP/NECA. 
The present study was set out to learn more about the effects of cigarette 
smoke on adenosine responsiveness of mast cells with respect to A2R expression, 
cell degranulation and A2R-related intracellular pathways. This subject had our 
interest since we previously showed that AMP is able to induce airway obstruction 
in smokers and patients with COPD, whereas the hyperresponsiveness to AMP 
reduced or disappeared following smoking cessation (5,7). 
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Little is known about the effects of cigarette smoke or CSE on adenosine related 
effector mechanisms. However, since AMP-induced airway obstruction is thought 
to act by binding of adenosine to the A28R on mast cells, our focus was on A2R 
expression and A2R- induced mediator release of HMC-1 cells. CSE appears to 
upregulate the expression of both A2A and A28 receptors, which was accompanied 
by mast cell degranulation and increase of intracellular calcium. Our findings on 
tryptase and histamine release due to cigarette smoke exposure are in line with 
other studies in which cigarette smoke extract induced degranulation of isolated 
canine mast cells (20), rat mast cells (21,3), and human basophils (22). In general, 
histamine release is not only correlated with increased intracellular calcium but 
also with decreased cAMP levels (23,24). Our data on CSE-induced degranulation 
confirm a relationship with intracellular calcium. 
Interestingly, we were able to prevent the effects of CSE-induced degranulation 
by adding a non-selective AR antagonist (theophylline). The prevention of CSE­
induced degranulation by theophylline was accompanied by an increase in cAMP 
and a decrease in intracellular calcium. Theophylline, a methylxanthine, is one 
of the commonly used bronchodilators of which the use has declined in recent 
years because of its narrow therapeutic index (25). The mechanisms underlying 
relaxation of airway smooth muscle cells due to theophylline is not completely 
understood but include inhibition of phosphodiesterases (PDE), thereby increasing 
the intracellular cAMP concentration (26), antagonism of adenosine receptors (27) 
and inhibition of the rise in intracellular calcium concentration (28). Thus our data 
are in line with these previous findings. Singh et al. described that mice that were 
prenatally exposed to cigarette smoke had a PDE4-dependent increase in airway 
responsiveness due to decreased levels of lung cAMP (29). This suggests that the 
observed CSE-induced mediator release of the HMC-1 cell in our study could also 
be PDE-dependent, and independent of adenosine related effector mechanisms. 
However, in the same study of Singh and co-workers, exposure of adult mice to 
cigarette smoke did not significantly alter airway responses, cAMP levels, or PDE 
activity (29), indicating that it remains unclear whether PDE-dependent decrease 
in cAMP could explain our in vitro results. Future experiments should assess 
whether mast cell mediator release as induced by CSE is PDE dependent. 
Theophylline has been demonstrated to exert not only a bronchodilating effect, 
but also other pleiotropic benefits, including anti-inflammatory effects and 
enhancement of mucociliary clearance (30). It has been shown that the anti­
inflammatory effects of theophylline can be mediated via activation of histone 
deacetylase (HDAC), and that this effect is independent of PDE inhibition. 
Interestingly, the effects of theophylline on HDAC appear to be enhanced under 
conditions of oxidative stress (31), a condition that can be induced by CSE. In 
the human macrophage-like cell line MonoMac6, CSE reduced HDAC activity 
and protein levels of HDACl, HDAC2, and HDAC3 (32). This indicates that the 
protective effects of theophylline against the direct effects of CSE in our study 
could also be due to abolishment of CSE-induced reduction in HDAC activity. 
During the performance of these experiments, selective A28R antagonists were 
not commercially available yet. For future experiments it is recommended to use 
specific antagonists. 
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CSE-induced degranulation was also prevented by the A2A receptor antagonist 
ZM 241385, albeit to a smaller extent. This was not expected, since A2A receptors 
show high affinity for adenosine and activation results in suppression of histamine 
and tryptase release from human mast cells (12). The observed increase in cAMP 
level is in line with the observed down regulatory effect on degranulation, but 
the enhanced intracellular calcium is not. Several effects of cAMP on intracellular 
calcium metabolism in smooth muscle cells have been described. These include 
a stimulation of calcium efflux, resulting in a lower intracellular cytosolic calcium 
(33-35), but also a stimulation of calcium influx and increase in free intracellular 
calcium concentration without causing an increase in muscle tone (36). The latter 
paper suggests that an increase of both cAMP and calcium can occur beside each 
other, but that the effect of cAMP overrules the effect of calcium. 
When AMP/NECA was added to our experiments, ZM 241385 did enhance CSE­
induced degranulation (decrease in tryptase positive cells) as was expected. 
This was not accompanied by changes in levels of cAMP or intracellular calcium. 
The observation that ZM 241385 enhances degranulation only in the presence 
of AMP/NECA and not with CSE alone suggests that the action of CSE alone is 
independent of the A2A receptor. 
We questioned whether CSE-induced effects could act via the A26 receptor, either 
directly by binding of CSE to the A26 receptor, or via endogenous adenosine 
binding to the A26 receptor. Von Borstel et al. showed that circulating adenosine 
potentiates blood pressure responses to nicotine in rats, apparently by enhancing 
the effects of nicotine in sympathetic ganglia (37). We tried to measure adenosine 
levels in culture supernatant of the HMC-1 cells, but they were under the detection 
level. Therefore, we will not speculate on endogenous adenosine produced by the 
HMC-1 cell itself and its role in CSE-induced degranulation of HMC-1 cells. 
In summary, we have shown that CSE upregulates both A2A and A26 receptors, 
which is accompanied by mast cell degranulation and an increase of intracellular 
calcium. These effects were prevented by the non-selective antagonisttheophylline, 
which was accompanied by increased cAMP and decreased intracellular calcium 
levels. Since the A2AR specific antagonist ZM 241385 did not show this effect, we 
conclude that CSE-induced effects may act via the A26 receptor, either directly by 
binding of CSE to the A26 receptor, or via indirect routes that enhance endogenous 
adenosine which can bind to the adenosine A26 receptor. Our findings suggest a 
possible role for specific A26R antagonists in the treatment of COPD. 
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Background.· Chronic Obstructive Pulmonary Disease (COPD) is mainly caused by 
smoking, and our group has previously shown that one-year smoking cessation 
improves airway hyperresponsiveness to adenosine-5'-monophosphate whereas 
airway inflammation persists or even increases in patients with COPD. Adenosine­
receptor signaling is implicated in chronic inflammatory airway diseases, such as 
asthma and COPD. We hypothesized that adenosine-related effector mechanisms 
could be involved also in the persistence and/or progression of airway inflammation 
in COPD following 1-year smoking cessation. Therefore, we compared adenosine 
and inflammatory mediator levels in sputum and expression of adenosine 
receptors on airway cells of COPD patients and asymptomatic smokers before 
and after 1-year smoking cessation. 
Methods: Sputum cytospins and bronchial biopsies of 11 smoking COPD patients 
and 15 asymptomatic smokers (before and 1-year after smoking cessation) 
were studied for the expression of adenosine receptors A1R, A2AR, A28R, and 
A3R. Adenosine, growth factors, and chemokines were measured in sputum 
supernatants. 
Results: At baseline, COPD patients had lower levels of adenosine and higher levels 
of vascular endothelial growth factor in sputum than asymptomatic smokers. In 
addition, COPD patients responded significantly different to smoking cessation 
than asymptomatic smokers which resulted in higher adenosine and monocyte 
chemoattractant protein-1 levels in sputum as well as higher percentages of A3R 
positive neutrophils and A1R positive macrophages. 
Conclusion: Adenosine-related effector mechanisms may contribute to the 
persistence and progression of airway inflammation in COPD following 1-year 
smoking cessation. 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is a disease caused mainly by 
smoking and it is characterized by chronic airflow limitation and a range of 
pathological changes in the lung (1). It is known that smoking cessation stops 
the accelerated lung function decline present in COPD (2,3). We found that 
smoking cessation improves both direct (methacholine) and indirect (adenosine 
5'-monophosphate, AMP) airway hyperresponsiveness (AHR) after 1-year smoking 
cessation (4). Interestingly, improvement of AHR was not associated with changes 
in lung function or sputum inflammation. In COPD patients who successfully ceased 
smoking for 1-year, overall airway inflammation persisted in bronchial biopsies, 
while the number of neutrophils, lymphocytes, interleukin (IL)-8 and eosinophil­
cationic-protein (ECP) levels significantly increased in sputum. In asymptomatic 
smokers who successfully quitted smoking, some inflammatory markers (e.g. 
sputum macrophages, eosinophils and IL-8) significantly decreased while others 
did not change (5). This indicates that factors other than inflammatory cells or 
measured mediators likely induced the observed improvement in AHR. 
Adenosine has been suggested to play a role in COPD (6). Patients with COPD are 
significantly more responsive to AMP than healthy smoking volunteers (7,8) and 
smokers have significantly increased concentrations of adenosine in the airway 
lining fluid (9). Recently a first report on the presence of adenosine receptors 
in lung parenchyma showed an enhanced density and decreased affinity of the 
adenosine receptors in subjects with COPD compared with control smokers 
(10). Adenosine is a purine nucleoside that is released during tissue hypoxia 
and inflammation. It has both pro- and anti-inflammatory features, which are 
mediated by four different G protein coupled receptors, A1 (Gi coupled), A2A (Gs 
coupled), A28 (Gs and Gq11 coupled), and A3 (Gs and Gq11 coupled). Activation of 
adenosine receptors (AR) can have different effects, depending on the cell type 
that is involved. Therefore, each receptor can be implicated, either beneficially 
and/or detrimentally in the inflammatory process of COPD. 
In this study, our primary aim was to investigate whether adenosine-related 
effector mechanisms could be involved in the persistence and/or progression 
of the inflammatory response in COPD following 1-year smoking cessation. 
Therefore, adenosine content and receptor expression in sputum (macrophages 
and neutrophils) and bronchial biopsies of smokers with COPD and asymptomatic 
smokers were measured, both before and after 1-year smoking cessation. Since 
activation of adenosine receptors can influence the secretion of mediators from 
inflammatory cells, we related changes in adenosine and its receptors with changes 
in growth factors and chemokines related to remodeling and inflammation that 





Bronchial biopsy and sputum material of 11 COPD and 15 asymptomatic smoking 
subjects who successfully stopped smoking for at least one year from the study 
of Willemse et al. were studied (patient characteristics Table 1) (5,4,11). In 
short, the main important in- and exclusion criteria for both groups were: COPD 
(according to the American Thoracic Society (ATS)/ European Respiratory Society 
(ERS) guidelines (12)): FEV/Forced Vital Capacity (FVC) post-bronchodilator 
<0.7, chronic respiratory symptoms for at least 3 months for 2 successive years. 
Asymptomatic smokers (ASM): FEV1 � 85% predicted, no chronic respiratory 
symptoms or airway obstruction. Participants in both groups were between 45 
and 65 years of age, had > 10 packyears smoking, smoked � 10 cigarettes/day, 
had reversibility to salbutamol < 9% of the predicted FEV1, and did not use 
inhaled or oral corticosteroids in the previous 6 months, had no signs of atopy, 
and no respiratory tract infections 1 month prior to the study. During the study, 
COPD patients only used �2 -agonists or ipratropium on a regular basis; inhaled 
corticosteroids were not used. Only in case of an exacerbation, a short course of 
oral corticosteroids was allowed. Before each measurement, subjects were asked 
not to use long or short-acting �2-agonists and/or ipratropium at least 12 hours 
before the test. They did not suffer from a respiratory tract infection nor used 
oral corticosteroids in the month prior to any of the measurements. 
The local medical ethics committee of our University Medical Center Groningen 
approved the study protocol and all subjects gave their written informed 
consent. 
Table 1. Patient characteristics 
COPD Asymptomatic smokers 
Baseline 
Subjects, n 1 1  
Age, yrs 57 (46-63) 
Sex (male/female) 7/4 
Packyears smoking 30 (15-66) 
Cigarettes, n/day 20 (10-40) 
FEV1 post BD, % pred 75.6 (44.4-100.4) 
FEV/VC post BD, % 58. 1  (30. 1-69.5) 
PC20 Mch, mg/ml 1.02 (0.25-78.4) 
PC20 AMP, mg/ml 46.2 ( 4.4-640) 







78. 1  (49.4-106)# 109.6 (95.5-134. 1)* 110.0 (90.0-133 . 1) 
57.5 (36.8-76.2) 78.8 (71.8-88.7)* 79.7 (68.9-92.3) 
13.4 (0. 13-78.4)# 33.4 (4.3�78.4)* 78.4 (1.8-78.4) 
640 (1.04-640)# 640 (73.9-640)* 640 (20-640}1= 
Data presented as median (range). * p < 0.05 vs. COPD; # p < 0.05 vs. baseline; * p < 0.05 change in COPD versus change in 
asymptomatic smokers (delta's). Abbreviations: 1-year SC, 1-year of smoking cessation; FEV1, forced expiratory volume in one 
second; VC, vital capacity; post BD, after 400 µg bronchodilator (salbutamol); % pred, percentage of predicted value; Mch, 
Methacholine; AMP, Adenosine 5'-Monophospate; PC201 provocative concentration of methacholine or AMP inducing a 20% fall 
in FEV1 
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Study design and smoking cessation program 
The study design and smoking cessation program have been described previously 
(5). Sputum cells and supernatant as well as bronchial biopsies were only used if 
present both before and after 1-year smoking cessation. 
Bronchoscopy and biopsy processing 
Bronchial biopsies were taken from the subcarinae of the right, middle, or lower 
lobe and processed as described previously (13). For immunostaining, sections 
(one per patient) were dried and fixed in acetone for 10 minutes and washed with 
PBS. The following polyclonal antibodies were used: rabbit anti-rat adenosine A1 
receptor, rabbit anti-canine adenosine A2A receptor, rabbit anti-human adenosine 
A28 receptor (all from Alpha Diagnostic International, San Antonio, TX, USA), 
and rabbit anti-human adenosine A3 receptor (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA). Antibodies directed against adenosine A1 and A2A receptors 
cross-reacted with human A1R and A2AR. The secondary antibody used was goat 
anti-rabbit biotin conjugated (SBA, Birmingham, AL, U.S.A.) and the tertiary 
antibody StreptABComplex peroxidase conjugated (DAKO, Glostrup, Denmark). 
As chromogen, 3-amino-9-ethyl-carbazol (AEC) substrate was used; tissue was 
counterstained with Mayers' Haematoxylin. Intensity of adenosine receptor 
expression in biopsies were scored in a blinded way (all by the same observer) 
with a semi quantitative three point scale, with sections scored as negative, 
positive, or strongly positive. In addition, the total number of positive single cells 
in the biopsy was counted. Since not all biopsies presented all tissue structures 
scored, numbers presented can vary between graphs. 
Sputum induction and processing 
Sputum was induced by inhalation of hypertonic saline and processed as 
described previously (14). Sputum samples consisting for >80% of squamous 
cells were excluded from analysis. Cytospins were dried and fixed in acetone 
for 10 minutes and washed with PBS for immunostaining. The same antibodies 
and chromogen substrate were used as described in the biopsy staining. Three 
hundred neutrophilic granulocytes and 300 macrophages were counted in every 
cytospin and scored as negative or positive; the percentage of cells expressing 
adenosine receptors was calculated. Due to the small numbers of lymphocytes 
present in sputum we could not reliably quantify adenosine receptor expression 
on this cell type. 
Measurement of adenosine in sputum supernatant using HPLC 
Adenosine was measured using a Waters 2690 Alliance Separation Module HPLC 
system (Waters, Milford, Massachusetts, U.S.A.) coupled on-line to a Finnigan 
TSQ Quantum Triple Quadruple Mass Spectrometer (Finnigan Thermo Fisher 
Scientific, Waltham, MA, U.S.A.). Chromatographic separation was performed 
with a C18, 3 µm, Atlantis column (Waters) 2.1 mm I.D. x 100 mm length using 
a gradient of mobile phase A (ammonium acetate 20 mM pH 7.0 in water) and 
B (ammonium acetate 20 mM, pH 7.0, in acetonitrile) at 0.2 ml/min. flow rate. 
Before measurements samples were pre-treated as follows: 100 µI of sputum 
supernatant was acidified with 20 µI of HCI 120 mM, then 200 µ I  of chloroform 
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was added to precipitate proteins and eliminate lipids. After vortexing and · 
subsequent centrifugation, 80 µI of the aqueous supernatant was transferred 
to a glass injection vial and 5 µI of this solution was injected into the HPLC- MS 
system. MS detection was performed using ESI ionization in positive ion mode. 
Multiple reaction monitoring mode (MRM) was used to increase the sensitivity. 
Adenosine was quantified using the transition m/z 260 > m/z 136 corresponding 
to the loss of the ribofuranose ring. Samples were measured in a randomized 
way, twice independently at two different days. Results were in good agreement 
within a maximum of 10% variation. The calibration line consisted of 8 points in 
the range of 5 to 1000 ng/ml adenosine in a mixture of PBS and water (pretreated 
in the same way as the study samples). Adenosine levels are presented as 
concentrations. 
Chemokine and growth factor measurement in sputum supernatant 
using multiplex ELISA 
Sputum supernatant contents (sensitivity level) of monocyte chemoattractant 
protein (MCP)-1 (10 pg/ml), "regulated upon activation normal T cell-expressed and 
secreted" (RANTES, 15 pg/ml), tumor necrosis factor (TNF, 10 pg/ml), epidermal 
growth factor (EGF, 15 pg/ml), fibroblast growth factor (FGF)-b (15 pg/ml), 
vascular endothelial growth factor (VEGF, 15 pg/ml), and platelet derived growth 
factor (PDGF)-BB ( <10 pg/ml) were measured using a human custom multiplex 
antibody bead kit from Biosource International, Inc. (Camarillo, California, USA). 
Standard solutions were diluted with sputolysin reagent (Calbiochem®, Darmstadt, 
Germany) to copy the effect of it on sputum content during processing. 
Statistical analysis 
Statistics were performed using a Wilcoxon signed rank test to assess differences 
. between both measurements within the groups, and a non-parametric Mann­
Whitney U test to assess differences between both groups at baseline. A value 
of p < 0.05 was considered significant. Correlations between parameters were 
investigated using a Pearson's Rho test. 
Results 
Adenosine receptor expression in bronchial biopsies 
The adenosine receptors (ARs) A2A' A28, and A3 were expressed by airway 
epithelial, endothelial, and smooth muscle cells in airway wall biopsies, and by cells 
(morphologically macrophages) in the submucosa in both COPD and asymptomatic 
smokers (Figure 1). In contrast, the A1 receptor was only expressed on a small 
number of cells (morphologically macrophages) in the tissue surrounding the 
airways. The pattern of expression of the four ARs was not different between 
COPD patients and their controls. 
The intensity of AR expression (scored semiquantitatively with immunohisto­
chemistry) is presented in figure 2. There was no significant difference in AR 
expression between both groups at baseline. The A2A receptor expression on 
airway smooth muscle decreased significantly after 1-year smoking cessation (p = 
0.025) in asymptomatic smokers, but not in COPD. A1R, A28R, and A3R expression 
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Figure 1. Adenosine receptor expression on bronchial biopsies from smoking asymptomatic (left 
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Figure 2. Semi-quantitative scoring of the immunohistochemical staining of adensoine receptor expression on bronchial biopsies from smoking asymp-
tomatic (AS) and COPD subjects, before and 1-year after smoking cessation. Structures present in bronchial biopsies were scored negative, positive, or 
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Figure 3. Adenosine receptor expression on neutrophils (A) and macrophages (B) in sputum 
of asymptomatic smokers (AS) and COPD patients, before and after 1-year smoking cessation. 
Significant differences are depicted in  the graphs. 
did not change with smoking cessation in both groups. In addition, no differences 
were found in the number of cel ls staining positive for all four ARs between the 
different groups. Total biopsy areas were similar for high and low numbers of 
positive cells. 
Adenosine receptor expression by sputum cells 
In sputum, al l  four ARs were expressed by neutrophils and macrophages of both 
COPD and asymptomatic smokers. There was no d ifference in AR expression 
between both groups at baseline. The percentage of A3R positive neutrophils 
increased significantly in COPD patients after 1-year smoking cessation when 
compared to baseline (p = 0.038). This change in A
3
R expression was significantly 
different from the change occurring in asymptomatic smokers (p = 0.050, Figure 
3A). No changes were detected in percentages of neutrophils expressing A1R, 
A2AR, and A26R. In COPD patients, the percentage of A1R positive macrophages 
increased after 1-year smoking cessation when compared to baseline (p = 0.017, 
Figure 3B), an effect that was not observed in asymptomatic smokers. Smoking 
cessation had no effect on expression of the other ARs on macrophages. 
No significant differences were found in percentage expression of all ARs on 
macrophages between COPD and asymptomatic smokers. 
Adenosine, growth factors, and cytokine levels in sputum supernatant 
Adenosine levels in sputum supernatant were significantly lower in COPD at baseline 
(p = 0.017, Figure 4A) than in asymptomatic smokers, whereas VEGF levels were 
higher (p = 0.020, Figure 4B). In addition, the change in adenosine levels with 
smoking cessation was significantly d ifferent in COPD and asymptomatic smokers 
(p = 0.023), as was the change in MCP-1 (p = 0.013) (Figure 4). No differences 
were detected in RANTES and other growth factors, involved in tissue repair (EGF 
and PDGF-BB) (Figure 4). Levels of FGF-b and TNF were below the sensitivity 
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Figure 4. Sputum adenosine (A), VEGF (B), EGF (C), PDGF-BB (D), MCP-1 (E), and RANTES 
(F) levels of asymptomatic smokers (AS) and CODP patients, before and after 1-year smoking 
cessation. * significant d ifference at baseline (p < 0.05) between AS and COPD, other significant 
differences are depicted in the graphs. 
Discussion 
We investigated the effect of smoking cessation on adenosine content and 
adenosine receptor expression in sputum and biopsies taken from COPD patients 
and asymptomatic smokers. Our most important observations were that COPD 
patients responded significantly different to smoking cessation than asymptomatic 
smokers with respect to sputum adenosine content, MCP-1 levels, and percentage 
of neutrophils expressing A3R, and macrophages expressing A1R. This resulted 
in an increased adenosine content (trend) and increased percentage of A3R 
positive neutrophils and A1R positive macrophages in sputum of COPD patients. 
In addition, smokers with COPD have a lower level of adenosine and a higher level 
of VEGF in sputum than asymptomatic smokers. 
Previous observations in these patients have elucidated that smoking cessation 
improved AHR, whereas .inflammation persisted or even increased in sputum 
of COPD patients (4,5). Since adenosine is impl icated in the development and 
persistence of inflammation, we investigated in  the current study whether the 
observed increase in (aspects of) inflammation in COPD could be explained by the 
presence of adenosine and the expression of adenosine receptors as measured in 
two different compartments of the airways, i .e. sputum and bronchial  biopsies. 
We confirmed the pattern of ARs expression that was recently described by 
Varani et al .  (10). Thus, the A2AR and A3R were expressed on bronchial epithelium, 
smooth muscle cells, endothelial cells, and infiltrating cells (mostly macrophages), 
whereas A1R was only expressed by a few cel ls (morphological ly macrophages). For 
A26R, Varani and co-workers detected expression on mast cel ls and macrophages 
only, whereas we additionally detected expression on epithelium, smooth muscle 
and endothelial cells, using the same antibody. With respect to the intensity of AR 
expression, no differences were found between COPD and asymptomatic smokers 
in our study. Interestingly, Varani et al .  detected an increased expression of A2AR 
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and A3R at the mRNA level, a decreased expression of A28R and no differences 
for A1 R mRNA in airway wall tissue of COPD patients. We did not study mRNA 
expression of AR. Other differences between both studies may be explained 
by differences in the clinical characteristics of the investigated participants. At 
baseline, we investigated current smokers, whereas both the COPD and healthy 
smoking groups of Varani consisted of a mixture of ex- and current smokers. Our 
data on the effects of 1-year smoking cessation show that this may have affected 
the results of the latter study. Also, some of the participants of Varani were older 
and had higher packyears of smoking. 
We report for the first time the expression of all four adenosine receptors on 
neutrophils and macrophages in sputum of COPD and asymptomatic smokers. At 
baseline, no differences were found between asymptomatic smokers and COPD 
patients. With respect to neutrophils, smoking cessation resulted in a significantly 
higher percentage of sputum neutrophils expressing A3R on their membrane in 
COPD, an effect not observed in asymptomatic smokers. The role of the human 
adenosine A3 receptor is poorly understood. mRNA for the adenosine A3 receptor 
is highest in the central nervous system, liver, and lung (15,16). A recent study 
showed that a ligand which combines adenosine A2A receptor agonist and A3 
receptor antagonist activity inhibits the release of preformed granule proteins 
from neutrophils (17). Another recent study showed that the A3R on neutrophils 
is additionally involved in neutrophilic chemotaxis (18). This is of interest since 
we previously showed that the number of sputum neutrophils significantly 
increased in COPD patients who successfully quitted smoking for 1 year. The 
role of these neutrophils is still not clear but theoretically they could contribute 
to the enhanced adenosine levels after smoking cessation in COPD. The exact 
contribution of adenosine in the persistence and progression of the inflammatory 
response is further dictated by the expression pattern of the four different 
adenosine receptors. 
The percentage of macrophages expressing the A1 R was increased in COPD patients 
after one year of smoking cessation. Recently, a role for the A1R on monocytes 
was described in modulation of angiogenesis (19). The A1R-selective agonist N6-
cyclopenthyladenosine increased VEGF production by human monocytes in vitro, 
and increased angiogenesis in a chicken chorioallantoic membrane model. In the 
present study, levels of chemokines and various growth factors were measured 
in sputum supernatant, to explain the increase in inflammation as a repair 
mechanism in the airways. Smoking cessation had a differential effect on MCP-
1 production in sputum supernatant when comparing COPD with asymptomatic 
smokers. Since this chemokine is involved in recruitment of macrophages, the 
observed relative increase in MCP-1 in COPD with smoking cessation compared to 
asymptomatic individuals is in line with the previously published observation that 
the number of macrophages decreases upon smoking cessation in asymptomatic 
smokers, whereas it persists in COPD (5). RANTES levels were similar in both 
groups and smoking cessation did not alter this. RANTES increases during COPD 
exacerbations (20) and is involved in chemotaxis of eosinophils. The percentage 
of eosinophils decreased in both COPD and asymptomatic patients after smoking 
95 
Chapter 6 
cessation (5). This thus could not be explained by RANTES. We found that COPD 
patients had higher levels of VEGF in sputum than asymptomatic smokers, which 
is in accordance with findings described by Rovina et al. (21) and other research 
groups describing higher VEGF levels in sputum of patients suffering from chronic 
bronchitis and lower levels in patients with emphysema (22,23,21). Cigarette 
smoking may upregulate VEGF, as suggested by an acute increase of VEGF 
plasma levels during smoking (24), yet we here show that smoking cessation did 
not reduce VEGF levels in both our groups. 
Finally, we observed that smoking cessation decreased levels of adenosine in 
asymptomatic smokers, whereas it increased (trend) adenosine levels in COPD 
patients. This is of interest and in line with the observation that a number of 
inflammation markers significantly decreased in asymptomatic smokers who 
successfully quitted smoking while the number of sputum neutrophils, lymphocytes, 
IL-8 and eosinophil-cationic-protein (ECP) levels significantly increased in COPD 
patients who successfully ceased smoking for 1-year (5 ). 
Conclusions 
We have shown that COPD patients respond significantly different to smoking 
cessation than asymptomatic smokers with respect to adenosine production and 
adenosine receptor expression. Our results may indicate that adenosine-related 
effector mechanisms are involved in the persistence and progression of the 
inflammatory response in COPD following 1-year smoking cessation. 
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In this thesis we aimed to shed more light on the role of adenosine and its 
receptors in asthma and Chronic Obstructive Pulmonary Disease (COPD). 
Adenosine and it receptors have our interest because of two main reasons: 
1) both patients with asthma and COPD respond with exaggerated airway 
obstruction after inhaling adenosine 5'-monophosphate (AMP), and 2) adenosine 
is involved as a key regulatory molecule in the pathophysiology of inflammatory 
diseases, mostly protective in nature but in certain scenarios injurious as well. 
Mast cells are thought to have a major role in AMP-hyperresponsiveness and 
these cells were, therefore, subject of in vitro studies, we used a mast cell line 
with additional cytokines as a model of mast cells in an asthma- or COPD-like 
environment. Furthermore, adenosine levels and the expression of adenosine 
receptors in vivo on inflammatory- and structural cells in lungs of both asthma 
and COPD patients were investigated with respect to their association with the 
level of inflammation. 
In this chapter our main findings are summarized and the role of adenosine 
and adenosine receptors (ARs) in chronic inflammation is discussed, with special 
attention to the role of mast cells in both asthma and COPD. 
Mast cells in asthma and COPD 
Mast cells play a prominent role in the pathophysiology of asthma due to their 
ability to release many pleiotropic autacoid mediators, proteases and cytokines in 
response to activation by both immunoglobulin (Ig)E-dependent and diverse non­
immunological stimuli (1). Following allergen challenge, mast cells secrete a.o. 
histamine, with subsequent acute symptoms due to bronchoconstriction, mucus 
secretion, and mucosal oedem�. Further pro-inflammatory and chemotactic 
mediators that are released contribute to the late asthmatic response and to the 
chronic inflammation that is a characteristic of asthma (2). Mast cells a re found 
near blood vessels in the lamina propria in normal human airways, but in asthma 
they migrate into the airway epithelium, airway mucus glands and airway smooth 
muscle where they are activated (3). Mast cells are also present in airway and 
lung tissue of COPD patients. For COPD, mast cells are thought to be mainly 
involved in neutrophil recruitment, tissue injury, and mucus hypersecretion (4). 
Our interest in mast cells in asthma and COPD mainly stems from the observed 
increase in bronchoconstriction upon inhalation of AMP in our asthma and 
smoking COPD patient populations, whereas this bronchoconstriction is virtually 
absent in healthy subjects (5-8). Bronchoconstriction upon AMP inhalation has 
been described to occur upon binding of adenosine to mast cells and subsequent 
degranulation of these cells (9-11). We therefore set up experiments that mimic 
the extracellular environment of mast cells in asthma (chapter 3) and COPD 
(chapter 5) to obtain more information about adenosine receptor expression 
and responsiveness in mast cells. In both the inflammatory (IL-4 and IL-13; 
asthma) environment and the smoking (cigarette smoke extract (CSE); COPD) 
environment (without AMP/NECA stimulation) we measured upregulation of A2AR 
and A28R expression, accompanied by increased degranulation. By incubating 
HMC-1 cells with antagonists for A2Rs in our CSE model, we obtained evidence for 
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the involvement of cigarette smoke in adenosine induced mast cell degranulation, 
since both the non-specific AR antagonist theophylline and the specific A2AR 
antagonist ZM241385 inhibited the CSE induced upregulation of A2AR expression 
and degranulation (chapter 5). For IL-4 and IL-13 we created an overnight 
incubation model, since it is believed that increased amounts of cytokines are 
present in asthma long before adenosine challenge. In this overnight model, 
expression of A2AR was lower in the "asthmatic environment" than in the control 
setting. Since A2AR is the receptor that is able to inhibit mast cell degranulation 
upon activation (12-14), we believe that there is less inhibition of degranulation 
with this lower A2AR expression, thereby favoring the actions of the mast cell 
degranulation inducing A28R. Theophylline also prevented the IL-4/IL-13/AMP/ 
NECA induced histamine secretion, suggesting a role for adenosine receptors on 
mast cells in adenosine responsiveness in asthma. 
Several studies on adenosine receptors and mast cells have been published in 
the literature. Already in 1978 Marquardt et al. described the potentiation of 
mast cell mediator release by adenosine (15). Nine years later, the same group 
published that chronic exposure to adenosine receptor agonists inhibited mast 
cell adenosine responsiveness (16). In the latter experiments, mouse bone 
marrow derived mast cells were chronically exposed to NECA, which induced a 
homologous desensitization of mast cell adenosine receptors. Chronic exposure 
to an adenosine receptor antagonist (aminophylline) was also studied and induced 
upregulation of adenosine receptors, resulting in functional hyperresponsiveness 
to exogenous adenosine (17). In our model, HMC-1 cells were only stimulated for 
1. 5 and 6 hours to AMP and NECA, and it can be assumed that this will not induce 
any alterations in AR expression as was caused by chronic agonist exposure as 
described by Marquardt et al. (16,17). Overnight culture of HMC-1 cells with IL-4 
and IL-13 also had no effect on AR expression as shown in chapter 3. 
Considerations about ,,. •• .,.,, ... ,a options for obtaiinin,a an in vitro model for 
mast cell studies 
We realize that the HMC-1 cell line, as a model to study adenosine responsiveness, 
has its limitations. We therefore set out to study human mast cells, as closely as 
possible mimicking the situation in men. However, when we started using this 
widely used, unmodified HMC-1 cell system it was not possible to obtain sufficient 
numbers of primary mast cells from progenitor cells in peripheral blood. Less 
than 1% of cells present in peripheral blood are mast cell precursor cells. As a 
consequence, very large volumes of blood would be necessary to obtain sufficient 
numbers of cells for in vitro stimulation experiments with proper controls. For 
future research in which mast cells are involved, it could be envisaged that mast 
cells might be isolated from surgical resection material (18), bone marrow (19), 
or cord blood (20). From surgical resection material, isolation of a cell suspension 
containing ±2.6% mast cells (± 3.6 x 105 mast cells/g of wet lung tissue) has been 
described (18). After subsequent magnetic affinity purification a purity of > 80% 
could be reached when carried out routinely (18). A relative disadvantage of this 
method can be that protocols describe that the start of isolation has to be within 
1 hour of tissue resection (18,21,22). Moreover, it is not certain to which extent 
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the behavior of mast cells derived from surgically excised tissue (often resected 
because of a lung tumor) would affect the outcome of the studies performed. 
Precursors can also be isolated from bone marrow and cord blood. They have 
to be cultured for 9-12 weeks to obtain a mast cell population with 93-100% 
purity, based on toluidine blue staining (19,20). For cord blood derived mast cell 
cultures, it has been described that a number of 3 x 107 mononuclear cells in 
culture will result in 1. 5 x 107 toluidine blue positive cells after 9 weeks (20). 
From this number of cells, at least 10 stimulations could be performed, with 
5 controls (based on 1 x 106 cells/stimulation). This means that cells could be 
stimulated only with agonists or antagonists specifically directed against one of 
the four different ARs, to confirm their role in mast cell degranulation/mediator 
release. A further disadvantage of this method is that these cells do not have the 
phenotypic characteristics of lung mast cells. Summarizing the pro's and con's 
of isolated mast cell cultures, we suggest that, isolation of mast cells from lung 
tumor resection tissue would be preferable, provided that it is as far away from 
the tumor as possible. Usually this type of lung tissue is derived from smokers 
with or without COPD. Isolation from the organ of interest ensures that the 
isolated mast cells will have the characteristics that will resemble those of mast 
cells localized in the lungs in obstructive lung disease and there is less need of 
time-consuming culture protocols. 
At the start of our studies, HMC-1 cells were selected to work with since it was 
described that the non-selective adenosine receptor agonist NECA increased 
IL-8 release (23) whereas neither A2AR nor A3R selective agonists increased pro­
inflammatory cytokine release. IL-8 production was blocked by the A28R-selective 
antagonist enprofylline (24). This suggested that A28Rs were able to mediate the 
pro-inflammatory effects of adenosine on HMC-1 cells, whereas A2AR is described 
to be able to dampen these effects (12). It remains unknown whether these 
findings are operative in the intact organism and how adenosine may influence 
antigen-induced mast cell activation via A28R. One of the limitations of the HMC-1 
cell line is the lack of expression of functional FcERI receptors (25). A human mast 
cell line that does express functional FcERI receptors is the LAD 2 (Laboratory 
of Allergic Diseases) (26,27). LAD 2 is a mast cell line derived from mast cell 
leukemia, like HMC-1, but it has no c-kit mutation and shows positive staining 
for chymase. In addition, a very recently described HMC-1 cell line derivative, 
modified with a construct to induce expression of FcERI on the cell membrane 
(28) could also be used in future studies on the interactions of adenosine and 
antigen-induced mast cells responses. 
Next to AR expression and agonist induced degranulation, AR-coupled intracellular 
pathways should be investigated more intensively, as described in chapter 5, to 
understand IL-4/IL-13 and CSE-induced adenosine responsiveness of mast cells. 
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Adenosine and adenosine receptor expression in chronic 
inflammation 
We were the first to report studies regarding adenosine receptor expression on 
inflammatory cells in peripheral blood and sputum in asthma patients and healthy 
controls, as well as sputum of COPD patients and asymptomatic smokers. With 
these results we partly addressed the difficulties presented in the conclusions part 
of chapter 2 of this thesis (29). Here we stated: "Thus far, the exact distribution and 
function of the different adenosine receptor subtypes in human airways remains 
largely unknown and this makes it difficult to establish which (combination of) 
receptors should be targeted'� Our studies have increased our knowledge about 
adenosine receptor expression and distribution in healthy and disease situations 
which could already give some indications about treatment directions. 
With respect to asthma, we showed as anticipated that asthma patients have 
an increased number of eosinophils in peripheral blood and induced sputum, 
and that these numbers further increased in sputum after allergen challenge. 
However, AR expression on blood eosinophils in asthma did not differ from that 
in healthy controls nor did it change upon allergen challenge, thus not explaining 
this increased eosinophil migration. Furthermore, we were not able to evaluate 
AR expression on sputum eosinophils because only few asthma patients had 
sufficient numbers of eosinophils in sputum to perform reliable scoring. 
Thus, it appears that allergen challenge does not directly affect eosinophil 
recruitment via adenosine receptor stimulation to the lung tissue, and other 
indirect factors like mediator release from mast cells, epithelial cells and other 
resident or inflammatory cells thus likely contribute to eosinophils attraction. Since 
an important role in chemotaxis is described especially for A3R on eosinophils 
(29), it would be of importance to include determination of the expression of 
this receptor in future studies (e.g. by performing eosinophil purification of the 
sputum samples before cytospin preparation). 
We detected a lower percentage of sputum neutrophils expressing A26R in 
asthma patients compared to healthy subjects (chapter 4). Since neutrophils play 
an important role in inducing and maintaining inflammation (30), and activation of 
A26R on neutrophils is described to inhibit transendothelial migration (31) and to 
increase the production of free oxygen radicals and oxidative stress in the lungs 
(32), upregulation of expression and activation of A26R could still be useful in 
the treatment of asthma, to inhibit airway inflammation. This seems in particular 
important in severe asthma, in which neutrophils play a central role (33). Although 
only a minority of asthma patients has severe intractable disease, our findings 
may have clinical relevance since particular this population of asthmatics incurs 
the highest costs of health care. Moreover, these patients are most affected in 
their daily life activities and quality of life. 
With respect to COPD, we detected a different response to smoking cessation 
with respect to percentages of A3R positive sputum neutrophils when compared 
to asymptomatic smokers (chapter 6). A3R activation on neutrophils is described 
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to induce cell migration (34). Since we provided suggestive evidence that smoking 
cessation induces an increased percentage of A3R positive neutrophils in COPD 
patients, it would be worthwhile to investigate whether treatment with an A3R 
antagonist would be useful in inhibiting neutrophilic inflammation in COPD. 
Notwithstanding this, we did not detect differences in AR expression in the airway 
biopsies between COPD patients and asymptomatic smokers. This could simply 
be due to the fact that both COPD patients and asymptomatic smokers were 
currently smoking at the start of the study, and this may have overshadowed the 
effects caused by the disease alone. 
Treatment with AR {ant)agonists 
Since we did not detect any differences in baseline adenosine receptor expression 
in biopsies or sputum of COPD patients compared to asymptomatic controls 
(chapter 6), it is difficult, based on our results, to select the receptor(s) that would 
be of most importance in the airways of COPD patients. We showed (chapter 
6), like Varani and coworkers (35), expression of all adenosine receptors in lung 
tissue of asymptomatic and COPD smokers. By performing saturation binding 
assays, Varani et al. detected differences between healthy and diseased subjects. 
The affinity of A1R, A2AR, and A3R was significantly decreased in patients with 
COPD compared with the control group, whereas their density was increased. 
The affinity of A28R was not altered, but the density was significantly decreased in 
COPD when compared to control subjects (35). For A1 R, we detected expression 
by a few alveolar macrophages in airway wall biopsies only (chapter 6), a result 
also shown by Varani et al. (35) .  In asthma, in a recent paper of Brown et al., a 
very strong expression of A1 R is described on bronchial epithelium and bronchial 
smooth muscle, whereas biopsies from healthy subjects showed very weak 
staining (36). This was striking, since in our and Varani's COPD studies almost no 
A1R expression was observed (chapter 6 and (35)). A main difference between 
the two expression patterns described (little expression in COPD (chapter 6/(35)) 
and strong expression in asthma (36)) is of course the disease which the subjects 
suffer from, though the antibodies used were different in all three studies as 
well. Both Varani et al. and we used commercially available polyclonal antibodies, 
whereas Brown et al. used a custom-made affinity-purified polyclonal antibody. 
To make a comparison between asthma and COPD and the antibodies used, all 
material should be stained with the same antibody, and the different antibodies 
should be used on the same material. Brown et al. conclude from their finding 
on A1R expression, that the sensitivity of asthma patients to inhaled adenosine 
combined with increased A1 R expression in asthma implies that this receptor 
plays a role in pathophysiology of asthma (36). Based on this study of Brown et 
al. targeting of A1 R in the airways of asthma patients might be a good option in 
the treatment of asthma. Since Varani et al. found differences in receptor affinity 
for three and differences in receptor density for all four of the ARs (35), for 
COPD, these might also harbor possibilities for therapeutic targeting. However, 
with respect to all ARs, in both asthma and COPD, use of agonists or antagonists 
can also have detrimental or beneficial systemic effects. Therefore, at this point 
it is hard to decide whether and which receptors would be a good option to 
block or to stimulate. More knowledge about expression and activation status of 
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adenosine receptors throughout the body is necessary before a single receptor 
or a combination of receptors can be selected as treatment target(s) in either 
asthma or COPD. 
Effects of adenosine receptors can differ from cell to cell and organ to organ. 
Therefore, as indicated above, it remains difficult to point to one receptor that 
could be stimulated or antagonized in the treatment of asthma or COPD in a way 
that no systemic harm is done. It has been suggested in the literature that all 
adenosine receptors on macrophages, except for the Az8R, seem to function as 
targets of AR agonist treatment in inflammatory diseases (37-39). Activation of 
ARs inhibits cytokine secretion from macrophages (40). Treatment with agonists 
will induce these effects, thereby indirectly decreasing inflammation caused by 
reduced production of inflammatory cytokines. Although we did not find any 
differences in AR expression between healthy and diseased subjects (neither 
in COPD nor asthma) there could be a difference in activation status or binding 
capacity of the receptors that could be useful in treatment. 
Two human trials have been published to assess effects of adenosine agonists 
in lung diseases, both investigating the AzAR agonist/A3R antagonist GW328267X 
(41,42). The AzAR is described to act anti-inflammatory, since intracellular cAMP 
levels are increased upon activation resulting in e.g. inhibition of degranulation 
of mast cells (12) and relaxation of vascular smooth muscle cells (43). A3R on 
the other hand is mainly described to act pro-inflammatory and activation of this 
receptor decreases intracellular cAMP levels. The first study with GW328267X was 
of Rimmer et al. in allergic rhinitis patients. In this study the drug appeared to 
have limited clinical benefit in both the early-phase and the late-phase response 
to intranasal allergen challenge (41). In a recent paper of Luijk et al., the same 
compound did not show any effects on the asthmatic response or the associated 
inflammatory response in asthma (42). The fact that GW328267X did not show 
the expected beneficial effects on airway hyperreactivity and inflammation could 
be caused by the fact that the drug did not reach the local sites where the 
action should take place. Alternatively, it could be due to inhibitory effects on 
A3R, as these effects may have counteracted possible beneficial effects of AzAR 
activation. Despite the fact that we detected a decreased expression of AzAR 
on blood neutrophils upon allergen challenge, and thereby less possibilities in 
inhibiting neutrophil chemotaxis, we believe that there still might be a possibility 
that treatment with a specific AzAR agonist (provided that there would be no A3R 
antagonist effect) is effective in dampening the airway inflammation and airway 
hyperreactivity upon local administration. 
Adenosine as a diagnostic marker 
By measuring the adenosine levels in sputum, we hoped to find differences between 
disease and healthy situation that could be used as a possible diagnostic marker. 
We did not detect any differences in adenosine levels in sputum from asthma 
patients and healthy control, nor after allergen challenge (chapter 4). However, 
we did observe a baseline difference between COPD patients and asymptomatic 
controls, and also a difference in the change upon smoking cessation by COPD 
and asymptomatic controls (chapter 6). Since there was a large range of variation 
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in sputum adenosine levels in both groups in the studies on asthma and on 
COPD, it is difficult to obtain a clear cut-off point in adenosine level by which 
it is possible to differentiate between diseased and healthy situations. In the 
literature, most studies in which adenosine levels were measured have been 
performed in animal models after administration of (chemical) compounds, which 
can not be easily compared to our results. One study in which adenosine levels in 
sputum of patients with cystic fibrosis (CF) were measured showed much higher 
concentrations (0.5-17 µg/ml) than those in our patient populations (0-175 ng/ml) 
(44). Differences in adenosine content between our and CF patients could be 
the consequence from the differences in methods of sputum collection. In the 
CF study, spontaneously expectorated sputum samples were used, whereas we 
used induced sputum samples. Another difference in methods is that we isolated 
cells from our sputum samples and for this purpose diluted the sample two times, 
whereas in the methods of Li et al. there is no description of cell isolation, which 
suggests that these samples were not diluted. When correcting for this dilution, 
adenosine concentrations of CF patients still remain much higher than those of 
asthma and COPD patients, which suggests the presence of a higher degree of 
inflammation in airways of CF patients, based on the knowledge that adenosine 
is produced at sites of inflammation. 
Adenosine receptor expression as a diagnostic marker 
Thus far, no selective, diagnostic blood markers for inflammatory conditions 
have been described. In our study in asthmatic patients versus healthy control 
subjects (chapter 4), we aimed to detect differences in adenosine receptor 
expression in peripheral blood that could serve as a possible diagnostic marker to 
differentiate asthma patients from healthy subjects. Since adenosine receptors 
have an important role in inflammation we hypothesized that differences would 
exist in adenosine receptor expression between asthma and healthy subjects, 
e.g'. higher expression of the pro-inflammatory A1R and A3R in asthma and 
higher expression of the anti-inflammatory A2Rs in healthy subjects. In our study 
population, no significant differences in baseline receptor expression were found. 
We did detect some differences upon allergen challenge in receptor expression 
in peripheral blood (decreased A1R on T cells and neutrophils, and decreased 
A2AR on neutrophils), but since the ranges in adenosine receptor expression 
before and after allergen challenge were overlapping, it is questionable whether 
they will be useful as a diagnostic marker in an individual patient. By including 
more asthma patients and patients with more severe disease, differences could 
become more robust, and possibly useful in differentiating between healthy and 
diseased subjects. 
Interestingly, for certain systemic conditions such as colorectal cancer and chronic 
heart failure it has been described that AR expression in peripheral blood reflects 
expression in the diseased organ and is therefore proposed to be a diagnostic 
marker (45,46). In these cases both peripheral blood and organ tissue was 
available. In order to investigate whether such a diagnostic marker can be found 
in asthma and COPD, future studies should include collection of both airway wall 
biopsies and peripheral blood. 
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Differences in AR expression between asthma and COPD 
Differences in AR expression between asthma and COPD are also of interest 
since this could indicate that both diseases might have to be approached by 
different treatment strategies. Main differences between both clinical studies 
(chapters 4 and 6), were age and the amount of smoking. In the asthma study, 
participants were younger and most patients were non-smokers (only few were 
ex-smokers), whereas in the COPD study all subjects were smokers at the start 
of the study. When comparing AR expression patterns in sputum, it is striking 
to see differences in adenosine receptor expression between both studies. For 
neutrophils, individuals with COPD had higher percentages of A1R and A2AR positive 
cells compared to individuals with asthma. In addition, when comparing both 
control groups, this led to the same observation, asymptomatic smokers from 
the smoking cessation study had higher percentages of A1R and A2AR positive 
neutrophils compared to the healthy controls from the allergen challenge study. 
In addition, percentages of A3R positive neutrophils and macrophages in sputum 
were lower for the subjects in the smoking cessation study compared to those 
in the allergen challenge study, which could also be caused by higher age and 
smoking status of participants in the COPD study. An age-related decline for 
ARs has been described at mRNA level for A1R and A2AR in rat hearts (47) and 
for A3R in mice myocardium (48), but so far effects of smoking on ARs have not 
been described. We also questioned whether these differences in AR expression 
between asthma and COPD could be explained by the function of the specific 
adenosine receptors or cell types in both diseases. Neutrophils are abundantly 
present in sputum of COPD patients (49), whereas in asthma larger number of 
neutrophils are present in sputum of patients with severe asthma rather than 
mild asthma (33). Both asymptomatic smokers and COPD patients had higher 
percentages of sputum neutrophils when compared to asthma patients and their 
healthy controls (chapter 4 and (SO)). As described for neutrophils in peripheral 
blood (chapter 4), A1R and A2AR have opposite effects on neutrophils. Activation 
of A1 R on neutrophils induces chemotaxis and increases the adherence to 
endothelial cells (51,52,53), whereas activation of A2AR on neutrophils reduces the 
adherence to endothelium (51), uncouples chemo attractant receptors from their 
stimulus-transduction-proteins (54), and inhibits the generation of toxic oxygen 
metabolites and degranulation (55) .  Since both receptors have opposite effects, 
in chapter 4 we already suggested the presence of a delicate balance between 
A1R and A2AR, in an attempt to counteract each others function, which may result 
in a positive or negative effect on neutrophilic inflammation. In both asthma and 
COPD expression of these ARs seems to be well balanced since the percentages 
of A1R and A2AR expressing neutrophils are about similar. This may be the case, 
but the activation status and thus functional activity could still be different, which 
may affect neutrophilic inflammation, as indicated above. 
Stimulation of A3R has been described to reduce neutrophil degranulation as 
induced by lipopolysaccharide or TNF. This means that lower expression can 
be interpreted as less inhibition of degranulation (56). When translating this to 
the lower A3R expression on neutrophils in asymptomatic smokers and COPD 
patients compared to the participants in the allergen challenge study, higher 
release of inflammatory mediators from neutrophils is suggested in asymptomatic 
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smokers and COPD patients. This could lead to tissue damage and inflammatory 
characteristics specific for COPD. 
Activation of A3R on macrophages has been described to inhibit LPS-induced TNF 
secretion (57), thereby influencing the cytokine environment and inflammation 
present. Again, this means that less A3R expression on macrophages from 
asymptomatic smokers and COPD patients compared to those obtained from the 
participants of the allergen challenge study, could lead to decreased inhibition of 
TNF release resulting in higher concentrations of this pro-inflammatory cytokine 
and inflammation in the airways, since TNF is described to enhance airway 
inflammation (58). 
Conclusion 
Taking our results from the studies in asthma, COPD, and their respective 
controls into account, our data is suggestive with respect to a possible role for 
A26R on sputum neutrophils in asthma (chapter 4 and described above), and A3R 
on sputum neutrophils in COPD (chapter 6 and described above). It is clear that 
we are only at the beginning to understand the involvement of adenosine and the 
expression of its receptors in asthma and COPD, and that further functional and 
clinical studies should shed more light on the exact involvement of adenosine and 
its . receptors in asthma and COPD. 
Future directions 
We recommend the inclusion of larger numbers of patients in order to increase 
the power and reliability of results in future studies on adenosine responsiveness 
and receptor expression in asthma and COPD. In addition, activation status of 
the receptors and functional coupling of the receptors to distinct intracellular 
pathways could be more important than measurem�nt of expression itself alone. 
If receptors are present but not able to signal upon binding of the substrate, the 
presence of high levels of adenosine may not have a functional consequence. 
Therefore, future experiments should aim at elucidating underlying mechanisms 
of AR expression/activation. For example, inflammatory cells isolated from 
peripheral blood or sputum could be stimulated in vitro with an adenosine receptor 
(ant)agonists to investigate intracellular pathways of adenosine receptor activation 
(e.g. cAMP and Ca2+). This could also be examined in leukocytes of healthy 
subjects. For asthma, patients with more severe disease should be included to 
obtain more and firm differences between healthy and disease, and especially, 
given our findings in neutrophils. Also the use of proper agonists and antagonists 
for adenosine receptors should be investigated further, since treatment with the 
proper medication could be able to tone down inflammation in the airways. 
In conclusion, with our results we confirm a role for adenosine and its receptors 
in asthma and COPD, since we detected differences in AR expression between 
healthy individuals and those affected by asthma or COPD. We also showed that 
mast cells cultured in the presence of IL-4/IL-13 (as an "asthma" environment) or 
CSE (as a "COPD-like" environment) show an altered response upon adenosine 
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stimulation. Therefore, we conclude that ARs may be important targets for the . 
treatment of both diseases. 
My main recommendation for future research would be to focus on the treatment 
with specific A2AR agonists in both asthma and COPD in an attempt to decrease the 
airway hyperresponsiveness upon AMP inhalation and to dampen the underlying 
airway inflammation. In order to investigate the underlying mechanism, it could 
be very useful to study adenosine receptor expression and responsiveness in 
primary cultured mast cells, preferably obtained from lung tissue. 
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Astma is een chranische ontstekingsziekte van de luchtwegen die vaak op de 
kinderleeftijd begint en meestal een leven lang aanwezig blijft met wisselende 
klachten van de luchtwegen. In de afgelopen 40 jaar is het aantal patienten met 
astma toegenomen, vooral het aantal kinderen. Wereldwijd hebben ongeveer 
300 miljoen mensen astma, wat.over het laatste decennium gestegen is met 50% 
(1). In Nederland heeft 15-20% van de volwassenen een vorm van astma (2). 
De chranische ontsteking van de luchtwegen is geassocieerd met een verhoogde 
luchtweggevoeligheid, het fenomeen dat astmapatienten met luchtwegobstructie 
reageren op het inademen van niet-allergische stoffen, waar gezonde personen 
niet op reageren, zoals sigarettenrook, koude lucht of mist. Kenmerkende 
klachten van astma zijn aanvallen van piepen, kortademigheid, benauwdheid en 
hoesten. Deze aanvallen komen vooral 's nachts en vraeg in de ochtend voor. 
De astma-aanvallen zijn meestal geassocieerd met variabele luchtwegobstructie 
die over het algemeen reversibel is. Deze reversibiliteit kan spontaan optreden 
of na behandeling met medicatie die de luchtwegen verwijdt (zogenaamde 
luchtwegverwijders) (3). 
Bij de chranische ontsteking van de luchtwegen spelen veel verschillende 
celtypen een ral. Dit ontstekingsproces is altijd aanwezig in de luchtwegen van 
astmapatienten, zelfs wanneer ze geen klachten hebben (4). De ontsteking 
wordt gekarakteriseerd door aanwezigheid van (gedegranuleerde) mestcellen en 
infiltratie van eosinofiele granulocyten en T-cellen in de luchtwegwand (5). 
Vernauwing van de luchtwegen kan ontstaan door het samentrekken van de 
spieren rand de luchtwegen, vochtophoping of zwelling van de luchtwegwand, 
verhoogde slijmpraductie en bindweefselvorming in de luchtwegwand en het 
omliggende weefsel (6). De ontsteking draagt ook bij aan de luchtwegobstructie 
veroorzaakt door allergenen (stoffen waarvoor men allergisch is). Inhalatie van 
een allergeen veraorzaakt doorgaans een vraege reactie, met luchtwegobstructie 
binnen 10 minuten na inhalatie, en een late reactie, met luchtwegobstructie 
8-24 uur na inhalatie van het allergeen. De late reactie wordt vergezeld door 
een toename van luchtweggevoeligheid. Luchtweggevoeligheid wordt in de 
polikliniek meestal gemeten door het inademen van een vernevelde stof 
(histamine of methacholine). De vernevelde deeltjes binden direct aan de 
gladde spiercellen rand de luchtwegen en de gladde spiercellen gaan als reactie 
hierap samentrekken. Luchtweggevoeligheid kan ook gemeten warden door het 
inademen van adenosine-5'-monofosfaat (AMP), deze stof werkt niet direct op 
het gladde spierweefsel, maar maakt histamine vrij uit mestcellen, waarna de 
histamine de spiersamentrekking kan veroorzaken. 
COPD 
Chranisch obstructief longlijden (Chronic Obstructive Pulmonary Disease, COPD) 
wordt voornamelijk veraorzaakt door sigarettenraok en luchtverantreiniging. 
Voorspeld wordt dat COPD in 2020 op de derde plaats zal staan van ziekten waaraan 
mensen overlijden (7). COPD wordt voornamelijk gekenmerkt door chronische 
luchtwegobstructie die met de jaren langzaam verergert. De luchtwegobstructie 
117 
Chapter 8 
gaat samen met luchtwegklachten, hoesten, slijm opgeven en benauwdheid. 
De ernst van COPD wordt gemarkeerd door lagere longfunctiewaarden en 
een versnelde afname van de longfunctie. Luchtweggevoeligheid komt veel 
voor onder COPD patienten en de ernst hiervan draagt bij aan de mate van 
longfunctievermindering. De ontstekingscellen die vooral aanwezig zijn in de 
luchtwegwand van COPD patienten zijn neutrofiele granulocyten, lymfocyten en 
macrofagen. Pathologische veranderingen die bijdragen aan de luchtwegobstructie 
zijn 1) het aantal en de grootte van de slijmklieren in de luchtwegwand, 2) 
ontsteking, 3) toename van de hoeveelheid bindweefsel en 4) afbraak van de 
longblaasjes (alveoli ) in de longen. Op dit moment is er nog geen genezing 
mogelijk voor patienten met COPD. Stoppen met roken is momenteel de beste 
behandeling, omdat dit de chronische klachten en ook de mate van longfunctie 
achteruitgang vermindert (8-10). Luchtweggevoeligheid komt bij ongeveer 70% 
van alle patienten met COPD voor, hierbij is het interessant dat rokers met COPD 
ook reageren op het inademen van AMP (11-13). Hierdoor wordt gedacht dat 
adenosinereceptoren van belang kunnen zijn bij COPD en geassocieerd kunnen 
zijn met de ernst en prognose van de ziekte. 
Adenosine en adenosinereceptoren 
Veel verschillende cellen, maar ook de verschillende mediatoren die door deze 
cellen uitgescheiden warden, spelen een rol in de chronische luchtwegontsteking 
bij astma. Adenosine is zo'n mediator. Adenosine is een stof die van nature 
voorkomt en wordt vrijgemaakt als afbraakproduct van het energiemetabolisme 
van de eel tijdens ontsteking. Adenosine kan zowel positieve als negatieve effecten 
hebben op cellen en weefsels. Adenosine is verhoogd aanwezig gevonden in 
longspoelingen van astmapatienten met zowel allergisch- als inspanningsastma 
(14), en de ontdekking dat adenosine hoeveelheden zelfs nog hoger waren na 
blootstelling aan een allergeen suggereert dat adenosine kan bijdragen aan 
de ontwikkeling en ernst van astma (14;15). Een verklaring voor verhoogde 
aanwezigheid van adenosine in de luchtwegen zou kunnen zijn dat de stimulatie 
van ontstekingscellen en de daaropvolgende samentrekking van glad spierweefsel 
tijdens het astmatische ontstekingsproces leidt tot een verhoogde zuurstof- en 
energiebehoefte, waardoor adenosine vrijgemaakt wordt. 
Adenosine aanwezig buiten de eel heeft zijn effect wanneer binding plaats vindt 
aan een van de vier adenosinereceptoren (AR), de adenosine A1, A2A' A28 en A3 
receptoren. Binding aan A2AR en A28R veroorzaakt voornamelijk effecten die de 
ontsteking rem men en binding aan A1 R en A3R veroorzaakt voornamelijk effecten 
die de ontsteking bevorderen. Adenosinereceptoren kunnen op veel verschillende 
cellen en weefsels aanwezig zijn, en activatie van deze receptoren kan voor elk 
celtype in combinatie met een specifieke adenosinereceptor een verschillende 
uitwerking hebben. De aanwezigheid en de rol van adenosinereceptoren is nog 
maar weinig onderzocht bij patienten met astma en COPD terwijl het specifiek 
stimuleren of juist remmen van een van de receptoren zou kunnen bijdragen aan 
behandeling van deze luchtwegen. 
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Gladde spiercellen rond de 
luchtwegen trekken samen 
Nederlandse samenvatting 
Figuur 1. Mestceldegranulatie door binding 
van adenosine 
Als adenosine bindt aan A28R, aanwezig op 
de celmembraan van de mestcel, wordt deze 
eel geactiveerd tot degranulatie. Tijdens de 
degranulatie scheidt de mestcel de in granules 
opgeslagen mediatoren uit, waaronder 
histamine. Histamine kan binden aan receptoren 
aanwezig op de gladde spiercellen rand de 
luchtwegen waarna deze gaan samentrekken 
en luchtwegvernauwing veroorzaken. Binding 
van adenosine aan A2AR werkt remmend 
op degranulatie. Figuur met toestemming 
overgenomen van Spicuzza et al. (21). 
Mestcellen komen voor in a l le weefsels. Ze spelen een belangrijke rol bij 
wondgenezing en parasitaire infecties (16;17) en bevinden zich op strategische 
plekken zoals in de huid, bloedvaten en slijmvliezen. Mestcellen binden lgE aan hun 
oppervlak door hiervoor receptoren tot expressie te brengen. Als een al lergeen 
aan twee IgE receptoren tegelijk bindt, scheiden mestcellen histamine uit (18). 
Oak wanneer de mestcel geprikkeld wordt door adenosine kan deze mestcel 
histamine en andere mediatoren vrijmaken. Luchtweggevoeligheid na inademing 
van AMP wordt waarschijn l ijk  veroorzaakt door degranulatie (uitstorten van 
mediatoren) van mestcel len en hierin l ijkt de Azleceptor een belangrijke rol te 
spelen (19). In tegenstel l ing tot de Az6R is voor de AzAR beschreven dat activatie 
juist kan beschermen tegen degranulatie (20-22). Het fenomeen degranulatie van 
mestcellen na binding van adenosine wordt uitgelegd in figuur 1 .  
Samenvatting van de hoofdstukken in dit proefschrift 
Astma 
Hoofdstuk 3 beschrijft onderzoek dat is gedaan i n  een cel l ijn van mestcel len, de 
Humane Mest Cel l ijn (HMC-1). We laten zien dat in deze cel l ijn  de expressie van 
zowel de AzAR als de Az6R nauwelijks verandert onder invloed van blootstel l ing aan 
AMP of en verwante stof (NECA). Uitscheiding van interleukine 8 (IL-8) daarentegen 
wordt aanzienlijk verhoogd. Incubatie van de cel len met IL-4 en IL-13, eiwitten die 
vaak voorkomen bij een a l lergische reactie en astma, zorgt voor een verhoogde 
expressie van AzAR als mede voor een toename in histamine uitscheiding, terwijl 
IL-8 juist verminderd wordt uitgescheiden. Incubatie met de combinatie van IL-
4/IL-13 en AMP/NECA gedurende 6 uur verhoogt de expressie van Az6R en de 
uitscheiding van IL-8. Tot slot resulteert overnacht stimuleren met IL-4 en IL-13, 
om het ontstekingsmilieu aanwezig bij astma na te bootsen, met daarop volgend 
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stimulatie met AMP/NECA in een verlaagde expressie van A2AR en een verhoogde 
uitscheiding van histamine. Uit bovenstaande resultaten concluderen we dat ter 
verklaring van verhoogde gevoeligheid voor adenosine, zoals gezien wordt bij 
astma, vooral een rol is weggelegd voor de A2AR. Expressie van deze receptor is 
verlaagd nadat cellen gedurende een langere periode gekweekt zijn met eiwitten 
die verhoogd voorkomen in de long bij astma. Hierdoor zou degranulatie van de 
mestcel na AMP inhalatie bij astmapatienten juist kunnen toenemen en dit zou 
de verhoogde gevoeligheid bij astmapatienten kunnen verklaren. Om ook bij de 
mens te kunnen onderzoeken of er verschillen zijn tussen astmapatienten en 
gezonde personen, hebben we een klinische studie opgezet. In hoofdstuk 4 
warden de resultaten van dit onderzoek beschreven. De astmapatienten kwamen 
drie keer naar het ziekenhuis, visite 1 betrof het induceren van sputum (methode 
met vernevelde zoutoplossing om het slijm uit de longen te kunnen ophoesten), 
visite 2 betrof een bloedafname en inhalatie van een allergeen, en visite 3 tot 
slot betrof een bloedafname en een sputuminductie. Deze studie liet zien dat er 
een lager percentage neutrofiele granulocyten die A28R tot expressie brengen 
in het sputum van astmapatienten aanwezig is, wanneer dit wordt vergeleken 
met gezonde controles. In bloed resulteerde allergeeninhalatie in een lagere 
expressie van de A1R en A2AR op neutrofiele granulocyten en A1R op T-cellen bij 
astmapatienten. Verder zorgde allergeeninhalatie voor verhoogde uitscheiding 
van IL-8 en aantallen eosinofiele granulocyten, en een verlaagd percentage van 
macrofagen die A1 R tot expressie brengen in het sputum. Deze studie laat zien 
dat allergeeninhalatie bij astmapatienten een sterk verlagend effect heeft op de 
adenosine receptorexpressie van een aantal verschillende celtypen, in bloed en in 
de long. Expressie van deze receptoren op de verschillende celtypen is betrokken 
bij celadhesie en migratie van en naar de long en geeft deels een verklaring voor 
verhoogde, dan wel verlaagde aanwezigheid van cellen in sputum en bloed van 
astmapatienten. 
COPD 
In hoofdstuk 5 laten we zien dat incubatie van de HMC-1 cellijn met 
sigarettenrookextract resulteert in een verhoogde expressie van de A2A en A28 
receptoren. Daarnaast geeft dit meer mestceldegranulatie wat vergezeld gaat 
van verhoogde intracellulaire calcium concentraties. De niet-specifieke AR 
blokker theophylline beschermde tegen de door sigarettenrook gernduceerde 
mestceldegranulatie, en ging vergezeld van verhoogde cAMP en verlaagde 
intracellulaire calcium concentraties. Theophylline beschermde ook tegen de 
gecombineerde sigarettenrook en AMP/NECA ge'induceerde degranulatie. De 
resultaten met de HMC-1 cellijn ondersteunen het fenomeen dat personen die 
roken (al of niet met COPD) verhoogd gevoelig zijn voor adenosine inhalatie bij 
de AMP provocatie test. 
Om de betrokkenheid van adenosine en adenosinereceptoren bij patienten met 
COPD te onderzoeken hebben we in hoofdstuk 6 gebruik gemaakt van reeds 
aanwezig patientenmateriaal van de "Stoppen met roken" studie van Brigitte 
Willemse (11;23;24). In deze studie zijn zowel rokers met COPD als rokers 
zonder luchtwegklachten een jaar lang begeleid in het stoppen met roken. 
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Op verschillende momenten tijdens de studie zijn luchtwegbiopten genomen 
en is sputum ge'induceerd. Voor onze studie hebben we gebruik gemaakt van 
het materiaal dat werd verzameld voorafgaand en 1-jaar na het stoppen met 
roken. Aan het begin van de studie hadden COPD patienten lagere adenosine 
concentraties en vasculaire endotheliale groei factor (VEGF) concentraties 
in hun sputum vergeleken met de rokers zonder luchtwegklachten. Verder 
reageerden de COPD patienten significant anders op het stoppen met roken dan 
rokers zonder luchtwegklachten. Bij COPD patienten resulteerde het stoppen 
met roken in hogere adenosine en monocyte chemoattractant protein-1 (MCP-
1) concentraties in sputum en hogere percentages A3R positieve neutrofiele 
granulocyten en A1R positieve macrofagen. Uit deze studie concluderen we dat 
adenosine receptorexpressie op de verschillende celtypen kan bijdragen aan 
de instandhouding en verergering van het ontstekingsproces in COPD na 1 jaar 
stoppen met roken. 
Conclusie 
De gevonden verschillen in expressie van adenosinereceptoren tussen gezonde 
deelnemers en patienten met astma of COPD suggereren dat er een rol is 
weggelegd voor adenosine en adenosinereceptoren in beide ziektebeelden. We 
hebben ook laten zien dat mestcellen gekweekt in de aanwezigheid van IL-4 en 
Il-13 of sigarettenrookextract een andere respons op adenosine stimulatie laten 
zien dan in de controle stimulatie. Hieruit concluderen we dat de verschillende 
adenosinereceptoren een belangrijk aanknopingspunt kunnen zijn voor het 
ontwikkelen van nieuwe behandelingsmogelijkheden bij patienten met astma en 
COPD. 
A�nbevelingen voor toekomstig onderzoek 
Voor toekomstig onderzoek zou ik willen aanbevelen de rol van specifieke AR 
(ant)agonisten in de behandeling van astma en COPD beter te onderzoeken, 
met name de mogelijkheden van een agonist voor A2AR. Behandeling met een 
AR agonist zou tot resultaat kunnen hebben dat de luchtwegontsteking en de 
luchtweggevoeligheid na inhalatie van AMP afneemt. Om het onderliggende 
mechanisme van de verhoogd aanwezige AMP-luchtweggevoeligheid te 
onderzoeken zou het in het bijzonder nuttig zijn om de AR expressie en respons 
te onderzoeken in primair gekweekte mestcellen, bij voorkeur afkomstig uit de 
luchtwegen. 
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